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 ABSTRACT 
 
 
Standard research practice has been to protect the rights of human 
subjects by providing an informed consent document that explains the study in 
clear and concise language. The problems inherent in writing this document are 
considerable and it is not known how effective these documents are in providing 
information and enhancing understanding about research participation.  
I have selected a clinical research trial involving older men to illustrate the 
challenge of providing sufficient information so that a person can make an 
informed choice. I describe the many human, educational and technological 
aspects that must be considered in developing an alternative method to the 
written informed consent process. I have developed a tutorial that can be tested 
within the clinical trial to compare the differences in informed consent methods. 
The research community is obligated to improve the informed consent process 
and these preliminary efforts are worthy of further development.  
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CHAPTER 1 
INTRODUCTION 
History of Human Subjects and Informed Consent for Clinical Research  
The history of human subject protection in clinical research in the United 
States has several important milestones. In 1906 the United States Congress 
passed the Food and Drug Act to address concerns about the quality and safety 
of food and medicines. The Nuremberg Code was written in 1947 in response to 
human experiments conducted during World War II. This code became the 
foundation of the Code of Federal Regulations, Title 45-Public Welfare, Part 46-
Protection of Human Subjects (45 CFR 46). In 1962 Congress passed the 
Kefauver-Harris Amendments to ensure drug efficacy and greater drug safety, 
and in what was the initial acknowledgement of the rights and voices of 
consumers, the Consumer Bill of Rights. In 1973, the Consumer Product Safety 
Commission was established, followed by the Bioresearch Monitoring program in 
1977, which focused on protection of human subjects. In 1981, 45 CFR 46 was 
revised to focus specifically on the elements of informed consent (Milestones in 
US Food and Drug Law History, 2005).  
In parallel to these events, medical science was exploring new research 
methods. The clinical trial emerged in the late 1950’s as the valid and objective 
research method to test the safety and efficacy of medical treatment. A clinical 
trial is defined as an experiment testing medical treatments on human subjects. 
Medical science has relied on this standard for almost five decades (Pianttadosi, 
1997). 
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Federal standards established and refined over the last century to regulate 
drug and device development have generated enormous growth within the 
pharmaceutical industry. Standards of medical care have changed to integrate 
the information that is generated from clinical trials in the name of improved 
health care and patient safety. For example, mammography and colonoscopy, 
originally used as diagnostic tests, are now used as routine screening tests 
intended to detect early changes that could result in breast or colon cancer.  
The process of conducting research to inform medical care, however, is 
dependent on people to participate as subjects.  Without people to volunteer for 
clinical research, medical science would not know enough about the effects of 
drugs on humans and therefore would not have the essential information needed 
to advance medical knowledge and ultimately improve public health. Animal and 
laboratory studies can provide data but only human beings can provide 
subjective information about the signs and symptoms associated with how a drug 
or device makes them feel.  
Throughout the history of medical research there have been several 
identified instances of misconduct wherein the rights of research participants 
were purposefully violated by those entrusted with their protection. One such 
instance occurred in Tuskegee, Alabama. Between 1932 and 1972, the United 
States Public Health Service (PHS) physicians and researchers conducted a 
study of African-American men with syphilis. Though it was discovered in 1940 
that penicillin could cure syphilis, treatment was purposely withheld from these 
men so that the research study was allowed to continue in order to further 
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evaluate the impact of the untreated disease. Three hundred ninety-nine men 
were told they had “bad blood” and were continuously misled about their health 
and subjected to many unnecessary and often risky medical procedures. 
Because these men were poor and had limited access to healthcare, researchers 
at Tuskegee were able to exercise control over what happened to these subjects. 
Worse, when 250 of these men registered for the draft during World War II and 
were ordered to get treatment for syphilis, the PHS intervened and had them 
exempted from this requirement. The experiment came to an end only when it 
gained media attention in 1972. By then many of the wives, partners and children 
of these men had contracted the disease and almost half of the men had died 
from syphilis or its complications (Jones, 1981). One of the consequences of this 
tragedy was the strong mistrust of the medical establishment that developed and 
persists among many African-Americans (Braunstein, 2008). 
Several other instances of unethical research were exposed by Dr. Henry 
K. Beecher, a professor of anesthesiology at Harvard Medical School. In 1966, 
Dr. Beecher published an article in the New England Journal of Medicine that 
gained attention outside of the medical community. He cited 22 examples of 
unethical research that violated the principle of voluntary consent in human 
subjects research. This article emphasized the thoughtless, as opposed to the 
willful disregard that researchers had toward some human subjects and 
heightened the awareness of researchers, the public and the press to the 
problem of unethical human subject research.  
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These disclosures coincided with professional and governmental action to 
curb unethical research practices. In 1964, the Declaration of Helsinki was 
developed by the World Medical Association (WMA) which established a set of 
ethical principles for the conduct of human research. In 1966 the American 
Medical Association (AMA) released Ethical Guidelines for Clinical Investigation, 
and the National Institutes of Health (NIH) published rules applicable to all 
federally funded human subject research. In 1981, additional laws and guidelines 
were specified to ensure the protection of human subjects in sections of the U.S. 
Code of Federal Regulations (CFR) and the International Committee on 
Harmonization (ICH) Guideline for Good Clinical Practice (NCI Guide to 
Understanding Informed Consent, 2001). 
The ICH GCP Guidelines have been established as the ethical and 
scientific quality standard and have their origin in the Declaration of Helsinki (ICH 
Guidance for Industry, 1996). The underlying ethical principles in these 
guidelines are that research must be conducted with the well-being of subjects as 
the most important consideration and that the research goals must be 
scientifically sound and focused on improving clinical outcome. Embedded in 
these guidelines, which have been adopted by the United States, Canada, Japan 
and the European Union, is recognition of the obligation of researchers to fully 
disclose information about the potential risks and benefits of research, as well as 
respect for the autonomy of individuals to make informed decisions based on full 
disclosure of this information (Sharp, 2004). It is this obligation that has led to 
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additional oversight to the protection of human subjects and the informed 
consent process.  
These codes and guidelines are based on the assumption that all involved 
parties are knowledgeable about research quality and ethics and are fully 
committed to their application, which is not necessarily the case. Academic 
medical centers have established Institutional Review Boards (IRB) composed of 
medical researchers and non-research members who are charged with 
protecting the rights and welfare of human subjects recruited into research 
studies. Because of the unique composition of this board, which includes 
physicians, nurses, researchers, and patient representatives, the IRB is well 
suited to evaluate each research study and the human subject informed consent 
documents that are written to accompany the research protocol. IRBs are 
granted the authority to disapprove or modify a research study based on human 
subject protections (45 Code of Federal Regulations 46, Subpart A, 2005). 
Though these ideal standards have been available to guide the conduct and 
review of medical research, the implementation of these research standards is 
often flawed at the organizational level. 
In 1999, a young man who voluntarily participated in an experimental gene 
therapy study at the University of Pennsylvania (Penn) died, not from his 
underlying medical condition but as a direct result of administration of a gene 
transfer product. This prompted a thorough examination of the entire medical 
research arena at Penn and within the Department of Health and Human 
Services (DHHS). DHHS suspended all gene transfer research at Penn and 
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other academic institutions nationally and convened an advisory committee on 
Oversight of Clinical Gene Transfer Research. Their recommendations focused 
on establishing rigorous requirements for accountability, reporting and 
transparency in all aspects of the scientific conduct of gene transfer research 
(Enhancing the Protection of Human Subjects in Gene Transfer Research at NIH, 
2000). Prior to this occurrence, the research administration at Penn functioned in 
an arena that had cursory oversight to the activities of individual researchers. It 
subsequently introduced more stringent standards and accountability for training, 
documentation, and inspection across the School of Medicine that had not 
previously existed.   
As a result of increasing awareness about the need to ensure safety of 
research subjects, as well as to compel researchers to register research 
activities, and document compliance with established Federal guidelines, the 
School of Medicine established the Office of Human Research to provide 
education and training about all aspects of conducting sound, safe research. This 
office was charged with developing activities that ensure the protection of human 
subjects and was authorized to oversee the specific procedures and methods 
being used across the university. In establishing itself as the local government 
proxy, the University would be able to evaluate research practices before the 
U.S. Government had reason to do so. One of the benefits is the heightened 
awareness that investigators and their staff have about human subject safety and 
their increased attention to the process of obtaining informed consent.   
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Though U.S. federal regulations specify eight elements of information that 
must be disclosed to research participants, (see Table 1), ethically valid informed 
consent demands more than just disclosure and as such, presents several 
challenges to the researcher (Flory, 2004).   
Table 1. Department of Health and Human Services (45 CFR 46.116) 
Essential Elements of Informed Consent 
 
Except as provided in paragraph (c) or (d) of this section, in seeking informed 
consent, the following information shall be provided to each subject:  
1. A statement that the study involves research, an explanation of the 
purposes of the research and the expected duration of the subject's 
participation, a description of the procedures to be followed, and 
identification of any procedures which are experimental;  
2. A description of any reasonably foreseeable risks or discomforts to the 
subject;  
3. A description of any benefits to the subject or to others which may 
reasonably be expected from the research;  
4. A disclosure of appropriate alternative procedures or courses of treatment, 
if any, that might be advantageous to the subject;  
5. A statement describing the extent, if any, to which confidentiality of records 
identifying the subject will be maintained;  
6. For research involving more than minimal risk, an explanation as to 
whether any compensation and an explanation as to whether any medical 
treatments are available if injury occurs and, if so, what they consist of, or 
where further information may be obtained;  
7. An explanation of whom to contact for answers to pertinent questions 
about the research and research subjects' rights, and whom to contact in 
the event of a research-related injury to the subject; and  
8. A statement that participation is voluntary, refusal to participate will involve 
no penalty or loss of benefits to which the subject is otherwise entitled, and 
the subject may discontinue participation at any time without penalty or 
loss of benefits to which the subject is otherwise entitled.  
 
Writing an informed consent document requires meeting at least four 
objectives. It must be (1) compliant with regulations and institutional legal 
requirements; (2) accurate; (3) informative; and (4) understandable (Sharp, 
2006). To write this document at a level of readability (defined as the ease with 
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which printed material can be read) that is at or below the eighth-grade level, 
which is the NIH recommendation that has been adopted by most institutional 
review boards, can be difficult (NCI Simplification of Informed Consent 
Documents, 2006). In a review of informed consent documents of 18 cancer 
clinical trials, Sharp (2004) found that only 1.0% of the informed consent 
documents were written at the eighth-grade level and that over the last decade 
most consent forms have become longer and more difficult to read.   
Researchers and bioethicists have recognized this problem of reading 
difficulty. Explaining a complicated research project in simple language in many 
pages of printed text does not ensure that it will be understood. There are many 
variables to consider including the educational level of the participant, differences 
in learning style; language used; and the medical urgency or level of illness 
(Jimison, 1998). If people do not understand what they are agreeing to, being 
informed is not assured.  
Purpose of Thesis 
I have selected a clinical trial that is being developed at the University of 
Pennsylvania, School of Medicine, to illustrate the challenge of providing 
sufficient information so that a person can make an informed choice about 
participating in a research study. I propose developing a multimedia tool to 
enhance the informed consent process by providing information in a familiar and 
accessible format instead of the standard paper document.  In Chapter 2, I 
provide relevant information from medical literature that describes the problem of 
measuring the outcome of the informed consent process. There is little literature 
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on this topic and a confounding factor is the difficulty in discerning what is 
remembered versus what is understood.  In Chapter 3, I explore the important 
human considerations that may be encountered in this complex clinical trial of 
older men. Chapter 4 describes the methods employed in developing the tutorial. 
Chapter 5 contains my conclusions about the final product, reflections on how it 
may enhance the informed consent process as well as the potential for 
acceptance as a useful tool in clinical research.  
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CHAPTER 2 
DESCRIPTION OF THE INFORMED CONSENT PROBLEM 
The informed consent document is the starting point for the dynamic 
process and exchange of information that occurs between the physician/research 
team and the potential participant over the course of the research experience 
(NCI Simplification of Informed Consent Documents, 2006). A review of the 
literature on the topic of informing patients for the purpose of obtaining consent 
(for medical treatment or research participation) indicates that there is not a great 
deal of quantitative research available.  
Flory (2004) reported a meta-analysis of 12 studies that compared the 
understanding of participants who had undergone a standard informed consent 
process to participants who had received an intervention to improve their 
understanding. The samples included adult men and women of all ages who 
were parents of pediatric patients, oncology patients, psychiatric patients, IV drug 
users, pregnant women and healthy volunteers. The interventions (defined as 
information delivery methods) varied among the 12 studies and included 
PowerPoint presentations, video, text reformatting as a booklet, and readability 
reduced to the 7th grade reading level. The results showed a consistent 
demographic predictor: research participants with higher education or reading 
levels had significantly higher level of understanding of information presented in 
the informed consent process, based on a post consent assessment. The results 
also indicated that levels of satisfaction were highest among participants who 
perceived that they had extended discussion time about the consent form (Flory, 
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2004). This suggests that the experience of discussion or personal interaction 
plays an important role among subjects who are considering participating. This 
resonates with bioethicists and medical researchers who emphasize the 
importance of conducting informed consent as a process and not just a form that 
requires a signature (Lavori, 1999).  
Agre (2003) analyzed eight studies of informed consent interventions that 
included modified print, computer and video consent formats and knowledge 
quizzes among adults. The mean age was 60 years; 57% were men. The 
findings were that better educated subjects scored better in the knowledge 
quizzes and that computer and video consent formats produced improvements in 
understanding over standard text media. These subjects also reported that the 
video clips of patients were the most useful part of the computer intervention.  
Wirshing (2005) reported a study comparing 261 adult medical and 
psychiatric patients who viewed a videotape that explained the informed consent 
process and emphasized good decision making in considering research 
participation, with a control group of healthy volunteers. The videotape 
repeatedly emphasized the need for subjects to be assertive in seeking 
information, and included role-playing vignettes of doctors and patients that 
reinforced the subject’s right to know and the physician’s responsibilities in 
providing clear explanations of the research procedures during the informed 
consent process. Results showed larger gains in knowledge among those who 
viewed the video about informed consent when measured before and after the 
process, as compared to the control group.  
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Hitchcock-Bryan (2007) reported a study of 77 cancer research patients 
who participated in an evaluation of an informed consent video. A post consent 
analysis indicated that watching the video did not measurably improve the 
subjects’ understanding of cancer clinical trials. However, subjects reported that 
the video provided important information, helped them educate their families and 
improved communication with their provider (Hitchcock-Bryan, 2007). This 
suggests that subjects perceived increased value and meaning despite a lack of 
benefit on the measured assessment of knowledge.  
Jimison (1998) designed a study that approached patients as consumers 
who demand a greater choice and involvement in their healthcare. A needs 
assessment was conducted around the topic of informed consent for medical 
treatment that included feedback from focus groups and individual interviews with 
medical and psychiatric patients. The primary findings indicated that most 
patients felt that the consent forms were too long, that the wording was too 
complex and that the level of detail was confusing. Patients reported that they 
preferred information presented to them in smaller segments and felt that the use 
of video made the information more understandable and the situation less 
stressful. Patients reported that one source of the stress occurred due to difficulty 
in concentrating on the printed text. The authors concluded that the use of a 
multimedia tool that offered the ability to proceed through the material at a self-
selected pace made the material more interesting to the patient and reduced 
dependence on the patient’s ability to read. Such a tool may have the potential to 
enhance and standardize the quality of the informed consent process. Since so 
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little is understood about how to make the process effective, however, the 
authors recommended that the patients or volunteers needs must be understood 
before a multimedia approach could be designed to address them (Jimison, 
1998). 
Dunn (2001) conducted a meta-analysis of 34 heterogeneous medical 
studies of adult men and women who were cardiology, surgical, radiology, 
cancer, and psychology patients. Dunn recommended that a variety of 
educational interventions to improve understanding of informed consent should 
be used to enhance the process, including video, multi-media and web-based 
technologies. Dunn argued that further investigation is needed about 
interventions to improve understanding because although the problem has been 
well described, studies that actually test intervention methods have been limited.  
Rosoff (1999) summarized the features of “prepackaged” informed 
consent education programs such as those presented on DVD or CD-ROM. The 
apparent benefits to the physician/researcher are that this method allows a low-
transaction cost transmission of fixed information. If accurate, it would provide all 
of the relevant and necessary information with significantly less time and effort 
than other (written) methods, and could document electronically the subject’s 
comprehension. For the physician, the gains are in efficiency and standardized 
information delivery. The apparent subject benefits are the receipt of a thorough 
explanation with full details on risks and consequences. In addition, the subject is 
able to access the material at their own speed without the pressure of the clock, 
and discuss it with their family/spouse, but not the researchers, in the privacy of 
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their home, instead of the physician’s office. If the technology permits, they can 
self-test their comprehension and review topics that are not clear to them.  
However, this technology eliminates the human interaction between the 
patient/subject and physician/researcher and eliminates the opportunities for 
spontaneous knowledge exchange with a professional that is the foundation of a 
personal medical relationship. Rosoff (1999) acknowledged that the presentation 
of information (in any format) does not assure knowledge and that it is very 
difficult to objectively measure understanding when information is complex. Yet, 
he asserts that comprehension is so important to autonomy and self-
determination that any approach that comes closer to assuring comprehension 
should be encouraged.     
Current research on the informed consent process is slow in catching up 
with the available technology offerings. Research studies focused on genetics 
and proteomics, for example, have resulted in the creation of longer and more 
complex informed consent documents. Medical researchers, focused on 
innovative scientific methods, have not applied the parallel technological 
innovations that are available to improve the informed consent process, nor has 
there much effort spent in measuring the outcomes of varied informed consent 
methods.  
The Testosterone Trial at the University of Pennsylvania, School of 
Medicine, is designed for men aged 65 and older. It has a complicated study 
design; six separate informed consent documents (five abbreviated and one 
comprehensive document); eligibility requirements in four separate areas; 
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potential health risks; and a significant time burden. A risk assessment of these 
factors served as an alert that the study may be difficult for potential subjects to 
understand, resulting in a low rate of recruitment and a weak study initiation 
phase. If this is the case, shortly after the study begins, the design and protocol 
will require revision, resulting in delays, inefficiencies and cost overruns. In an 
effort to mitigate this risk and the possible negative impact on the launch of the 
study, I have developed an informed consent multimedia tool for this study to 
serve as a supplement to the written form which I propose will add clarity to the 
issues described above. The Research Informed Consent Multimedia Tutorial 
(developed as a Powerpoint presentation) in Appendix A provides specific 
information about the Testosterone Trial as well as the essential elements of 
informed consent listed in Table 1.  
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CHAPTER 3 
HUMAN FACTORS  
This clinical trial, designed to test the efficacy of testosterone, is currently 
under review and is expected to begin in January 2009. Based on research by 
Jimison (1998), Dunn (2001) and Rosoff (1999), there are several important 
human factors to consider in developing the appropriate tool for use in this 
research study including cognitive characteristics of older adults; learning styles 
of individuals; knowledge assumptions; use of technology; and the physician-
subject relationship.  
It is important to note that the participants in the Testosterone Trial are 
research subjects who may or may not be patients of study investigators. As the 
clinical settings will vary among the 18 research sites, it is possible that the 
participants are not patients, and the investigators are researchers but not 
healthcare providers to the participants. The terms subject and participant can be 
used interchangeably; however, the term patient implies that a person is 
participating in a health care relationship with the investigator/physician.  
Another feature of this clinical trial is that it will be conducted as a double-
blind experiment. This means that participants are randomly assigned to the 
treatment or placebo group and that neither the subject nor the researchers will 
know which treatment a given subject is receiving.  These methods are used to 
reduce the unconscious and deliberate human influence on treatment 
assignment and evaluation, and mimic the laboratory model of scientific 
experimentation (Piantadosi, 1997). 
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Cognitive Characteristics of Older Adults 
Aging is associated with a gradual and progressive decline in many 
aspects of cognitive function. The terms age-associated memory impairment 
(AAMI) and late-life forgetfulness (LLF) are used to describe a condition that is 
characterized by temporary memory lapses in otherwise healthy individuals 
(Smith, 1991). The typical symptoms of AAMI include difficulty in recalling names 
and words, and in associating a name with a face. In a memory study of 527 
adults ages 55 to 98, Smith and Ivnik (1991) reported that age-related memory 
changes vary depending on several factors including educational experience, 
activity level and motivation. It is a challenge for clinicians to distinguish normal 
age-related memory changes from early dementia, and there is lack of 
agreement regarding the criteria for detecting the difference. Larabee and Crook 
(1994) reported that the prevalence of AAMI among adults older than 50 ranges 
from 39 to 85% and increases with age.   
Sugarman, McCrory and Hubal (1998) performed a meta-analysis of 99 
published empirical research measures on informed consent with older adults. 
They found consistent evidence of impaired understanding of informed consent 
information in older subjects and those with less formal education. Their 
recommendations to improve the informed consent process included 
simplification of text, and novel formats and tools that promote interaction to 
enhance comprehension. Recognizing these natural, complex outcomes of 
aging, it is prudent to assume that many of the men who read the Testosterone 
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Trial informed consent document will have some difficulty remembering the 
details described in its 17 pages (see Appendix B). 
Recall alone does not imply understanding; indeed, there is a lack of 
clarity in defining understanding. The complex cognitive processes involved in 
reading, attention and memory are called by several different terms such as 
understanding, knowledge, comprehension, and recall that do not mean quite the 
same thing but are often used interchangeably. Dunn (2001) reported a meta-
analysis of 34 clinical studies which included people of all ages, in which 
problems with understanding the research consent form were widely reported. 
These included lack of awareness about being a subject in a research study, 
poor understanding of placebo and randomization, confusion about risks and 
benefits, lack of awareness of the ability to withdraw from the study without 
consequence, and therapeutic misconception which is the belief that treatment 
decisions are being made solely for the individual’s benefit. The problem of 
therapeutic misconception occurs more often when a subject’s only role is as a 
participant in a research study, compared to the subject who is also a patient in a 
healthcare relationship. There are studies that acknowledge the difficulty in 
measuring memory for presented information versus comprehension in 
assessing understanding of informed consent information, but the number of 
studies that test methods to improve the process has been limited.  
Learning Styles of Individuals  
Adults bring many years of learning experiences with them to any new 
learning situation, integrating new learning with prior learning. In order to meet 
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the learning needs of adults the content of any material must be relevant; if 
adults see the usefulness of the material presented, their motivation to learn 
increases. Adults also tend to prefer active learning that is related to their real-life 
situations as well as self-directed learning (Disabilities, Opportunities, 
Internetworking and Technology, Adult Learning, 2006). 
This is relevant because participation in this research is voluntary; only 
those men who are eligible and motivated by the potential for improvement in the 
four research realms will reach this stage of the enrollment process. I believe that 
this multimedia tutorial will enhance the informed consent process for the adult 
learners in this study as it allows self-directed learning, in which the learner has 
some control over the pace and content of the program.  
The men who volunteer to participate in the Testosterone Trial will be a 
diverse group of 1200 older men varying in race, level of education and 
geographic location. In developing a multimedia tool, it is important to 
acknowledge that they are also individuals who will have different learning styles. 
It has been reported that educational level is directly correlated to level of 
understanding of informed consent, which is one of the reasons that the 
readability of informed consent documents has been established at the eighth 
grade reading level. But this one parameter does not consider the many other 
aspects of taking in information that are relevant.  
VARK (Visual, Aural, Read/Write, Kinesthetic), developed by Flemming 
(1987), is one of the many dimensions of learning preferences, and is focused on 
the way that an individual takes information in and puts information out in a 
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learning context. VARK is a mechanism for profiling individual learning 
preferences, but not necessarily strengths. There are some consistent reports of 
matches between VARK results and perceived preferences; however, statistical 
data are not yet available to prove the validity and reliability of VARK. 
In order to reach every learner, media should be constructed to address 
the VARK preferences for obtaining knowledge of the audience. The VARK data 
indicate that men have more kinesthetic responses than women but overall 
learners are distributed across the four domains. There are limitations to the 
kinesthetic learning experiences that the multimedia tool can provide; however, 
the tutorial will include visual, aural, and read/write components to address those 
learning aspects. (See Appendix C, Multimedia Tool Development Proposal). 
Knowledge Assumptions 
Recruitment techniques in the Testosterone Trial will vary widely. One 
technique will use national media, local media and mass mailings targeted at 
older men who will be asked to contact the research center if they are interested 
in a testosterone research study. This subject generated contact implies only that 
respondents are willing to learn more information. No further assumptions should 
be made about what respondents know about research or testosterone. Holden 
(2005) reported a study of men aged 40-79, wherein 27% of respondents were 
not familiar with the term testosterone; more men (40% of respondents) in the 
older age group (60-79) indicated unfamiliarity with the term.  
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Pilot Study 
I conducted a pilot study of structured individual interviews with eight men 
who appeared to be candidates for the Testosterone Trial study. The interview 
instrument is included in Appendix D. This group was a convenient sample of 
friends and family members; therefore, the results should be considered 
exploratory data only. The instrument and process warrant further evaluation and 
refinement. I recruited eight White/Caucasian men ranging in age from 65-85 
years (Mean = 73.7 years). Educationally, 3 (37.5%) attended or graduated from 
college; 5 (62.5%) had a high school education or less (see Table 2). A complete 
summary is included in Appendix E.  
Table 2. Pilot Study Participant Demographic Characteristics (n=8) 
Education Number (%) 
7th to 12th grade, no high school diploma  1 (12.5%) 
High school graduate or equivalent (e.g. GED)       4 (50%) 
Some college education, but not completed degree  1 (12.5%) 
College graduate       2 (25%) 
 
Subjects and Methodology 
Each man read the consent form to himself after which I conducted an 
interview with him and collected information about his reaction to several 
sections of the consent form, including understanding the four trials, the 
Interactive Voice Response system, placebo, and risks, as well as willingness to 
discuss this study with his spouse/significant other/family member and physician, 
and capacity to use other media to explain the clinical trial. The interviews were 
conducted at the respondent’s homes between February 12 and March 10, 2008.  
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The respondents had many shared opinions. The comments that I 
recorded during the interviews provided much more information about the 
preconceived notions, knowledge and understanding that the interviewees had, 
than the dichotomous responses to the questions. 
I had extensive discussions with five of eight men about use of a placebo. 
None of the men interviewed had ever participated in a research study. They 
stated that they understood the difference between the active and placebo 
medications used in the study, but they also said that they would not want to be 
in a study where they might use a placebo instead of testosterone gel. These 
men learned about testosterone primarily from sports news. They knew that it 
was available by prescription from a physician and felt that there would be no 
need to participate in a trial if they were inclined to use testosterone. (I explained 
that testosterone should only be used if the level of that hormone is significantly 
low. Also, I explained about the importance of monitoring adverse effects.) These 
discussions suggest that some men may have had trouble understanding and/or 
accepting the value in using a placebo in this study and that it is important to 
include a clear explanation of the placebo in the tutorial and to evaluate the level 
of understanding.  
Addressing the ethical concerns of the placebo controlled trial has been 
controversial and debated in the medical literature for many years. Opponents 
claim that it is unethical in that it places scientific rigor over the needs of people. 
Proponents explain that regulatory oversight of research and the informed 
consent process ensure that its use is ethical, provided participants understand 
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the rationale and risks if assigned to the placebo condition (Emanuel, 2001). It is 
probably naive to assume that regulatory oversight in academic medical centers, 
local clinics, doctor’s offices and wherever research is conducted, can provide 
the needed rigor and standardization to protect research subjects. Bok (1978) 
warned that the use of placebos is not innocuous, that the safeguards against 
this practice are few or nonexistent both because it is secretive in nature and 
because it is condoned but rarely discussed in the medical literature and that it 
undermines the medical relationship.  
The men in this sample had a wide range of accurate and inaccurate 
information about prostate cancer. Their comments suggest that the experiences 
of individual men they knew seemed to influence their perceptions more than 
information they heard from doctors. All of the men (100%) expressed  concern 
about prostate cancer; 75% were not clear about the effect of testosterone on 
their risk of prostate cancer. I discussed “occult” prostate cancer with all of these 
men and found that half of the men understood the concept of occult prostate 
cancer but that the term “occult” in this context created confusion. This is the kind 
of practical information that helped me write the risk section of the tutorial, which 
I found to be the most difficult.   
Use of Technology  
It would be a mistake to assume that the men in the testosterone trial will 
be able to easily use a web-based tool or a DVD to view the tutorial at home. 
Three major studies conducted between 2003 and 2005 revealed that 25 - 41% 
of adults aged 65 and older use the Internet (Doing the Math, Older Adults 
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Online, 2005). In this sample of eight men, five (63%) did not own a computer 
and 75% did not feel comfortable accessing the tutorial from a website. This is 
important information to know about potential participants. It suggests that the 
tutorial may be viewed primarily at the research clinic during the baseline visit, 
under the guidance of the research staff; however, it must also be portable so 
that men who are facile with technology can take the tutorial home to read and 
answer the questions. The method must be uncomplicated and reliable however 
subjects prefer to access the tutorial. A brief training or practice session should 
precede distribution of the DVD for home use to ensure that users have the 
ability to access the media and know how to use the features of the tool.  
This also suggests that one of the potential benefits of the tutorial, the 
transmission of information with less time and effort by the research staff, may 
not be realized.  A common research practice used to gain efficiency in the 
informed consent process is to distribute the document and other educational 
information, such as a study fact sheet, to the subject even before it has been 
determined that he is eligible. In this study, a man who has completed the 
screening visit could be given the informed consent document and tutorial to take 
home, even though his eligibility status has not yet been determined. When it is 
verified (by confirming lab data) that a man is eligible, he can be contacted and 
instructed to read the form and complete the tutorial at home, before the next 
research clinic visit. There are potentially negative consequences to this 
approach. If a man has questions, he has no one to ask and if he encounters 
technological trouble using the tutorial he may become frustrated and abandon 
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the tutorial. In addition, the introduction of technology into the informed consent 
process may dilute the compassionate, human exchange that forms the core of 
the medical relationship (Rosoff, 1999). Therefore, it could be risky to rely on 
technology to meet the needs of subjects during the informed consent process, 
unless the research team continues to invest the time and energy needed to 
thoroughly discuss the research and address all of an individual’s concerns. 
Ultimately it is the combination of the technology and the human elements that 
will determine how well the tutorial will be received.  
Physician-Subject Relationship  
The current practice of obtaining informed consent relies on the 
physician/subject relationship and is based on the assumption that this activity is 
worthwhile to the physician and the subject (Rosoff, 1999). In introducing 
technology to educate subjects about research, it is important to consider how it 
could diminish the important bonding process that takes place when a doctor and 
subject engage in a meaningful conversation about their health or quality of life. It 
is essential that human interaction is not reduced because a tutorial or other 
electronic aid is used. In obtaining informed consent, physicians must be 
committed to meeting a subject’s emotional needs in addition to their 
informational needs.     
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CHAPTER 4 
METHODOLOGY 
Three subject matter experts contributed to the development of materials 
for the tutorial. The design team included Peter J. Snyder, M.D., Principal 
Investigator of the Testosterone Trial. Dr. Snyder is an endocrinologist at the 
University of Pennsylvania, School of Medicine, and has conducted testosterone 
clinical research for over 30 years. Dr. Snyder was the subject matter expert for 
the medical content presented in the tutorial.  Gregg Fromell, M.D., Director of 
the Office of Human Research (OHR), at the University of Pennsylvania, School 
of Medicine, provided expertise on research education, training and compliance.  
Dr. Fromell leads the initiative to develop standard tools, methods and teaching 
materials for the Penn OHR and has extensive experience in evaluating informed 
consent documents. He was the subject matter expert on the essential elements 
of informed consent, readability and format of the tutorial.  Barry Dornfeld, Ph.D., 
is an Educational Media Consultant and co-leader of the Center for Applied 
Research (CFAR) Action Learning initiative. Dr. Dornfeld provided expertise in 
development of content and organization of biomedical knowledge and served as 
a reviewer of the entire multimedia tool.  
The initial project to develop an informed consent video was modified to a 
multimedia tutorial to reduce delivery time and facilitate anticipated revisions to 
the project following review by the research network investigators. The design 
team focused on developing a multimedia tutorial that would enhance 
understanding of the information presented during the informed consent process 
V1.20080627 
 27
for the subjects; meet established institutional guidelines for research; be 
appropriate to subjects; be interesting and attractive to users; be portable as well 
as accessible from the internet. 
Print media is inexpensive, convenient and familiar; however, it is not 
interactive and often requires higher literacy levels of users. Advances in 
computer technology have enabled the construction of multimedia learning tools 
from online libraries of static and dynamic images, but it is difficult to know what 
changes for the learner when you add pictures to words (Elloumi, 2008). Mayer 
(2001) defined multimedia as the presentation of material using words (printed 
and spoken text) and pictures (static graphics and video). In proposing to use a 
multimedia tool in addition to text, there are several adjustments to consider.  
The tutorial structure was based on the model designed by the National 
Library of Medicine (NLM) which provides a comprehensive program of 
authoritative health information tools (Medline Plus, 2008). The content is in 
alignment with but not identical to the informed consent document as the tutorial 
is meant to work in conjunction with the document. The pilot test results helped 
shape the content significantly in terms of emphasis on explaining the four trials, 
use of placebo, and risks. It also suggested that some words were confusing so 
we avoided terms that require specialized knowledge. The tutorial was developed 
in parallel with the interviews as well as continuous review by the design team. It 
was reviewed at regular intervals by Dr. Snyder, Dr. Fromell and my colleagues 
in the Clinical Research Computing Unit. Table 3 identifies the content of the 
tutorial modules.   
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Table 3. Testosterone Trial Tutorial Table of Contents 
Modules Number of Slides 
Introduction 18 
Participating in the Trial 11 
4 Testosterone Trials in 1 17 
Tests and Procedures 11 
Risks and Benefits 18 
More Important Information 11 
Summary   8 
 
The tutorial that accompanies the Testosterone Trial informed consent 
document was designed to enhance information in order to facilitate balanced 
decision-making. Based on data from Rosoff (1999), it seemed important to 
simplify the content, permit self-paced learning and support interactive learning. 
We wanted the users of this tutorial to make sense of what they see and hear.  
The output of responses to the “Check Your Understanding” questions is 
provided to guide the research team about the topics that should be reviewed or 
reinforced with the subject. Figure 1 presents two questions from the Risks and 
Benefits module.  
Figure 1. Check Your Understanding about Testosterone Risks 
Check Your Understanding 
Using testosterone will cause you to have sleep apnea.   True 
 False 
You will have a prostate biopsy at the end of the study.  True 
 False 
 
I avoided focusing on the technology over the content and have included 
features that are functional without embellishments. The tutorial was developed 
to incorporate brief video streams to present information from men who resemble 
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the subjects in the study, and from physicians who convey concern for the health 
and safety of participants in the study. It is important that these images are 
appropriate as well as interesting to attract the subject’s attention.  
The tutorial will be implemented and accessed from a secure Internet 
website; it will also be portable to permit access from a stand-alone computer 
system, via DVD. It will be introduced with a brief explanation of its purpose 
which is to provide information about the study, not specific medical advice. It will 
explain that the video and pictures have been included to enhance the text. The 
‘Check Your Understanding’ questions are asked to verify that the subjects 
understand the material as presented at that time. By documenting responses 
within the program, the tutorial will provide those administering the informed 
consent process the opportunity to review content that is not clear by examining 
the subject’s responses, thereby verifying understanding. This method of 
assessment does not address the problem of understanding versus recall, nor 
does this tutorial distinguish between short and long term recall. However, it has 
the potential to enhance satisfaction with the informed consent process, provide 
added value to potential subjects and may serve to reinforce learning by 
repeating information that is provided to them in the informed consent document 
in a media that is familiar, accessible and clear (Jimison, 1998).  
The benefits of the tutorial are that it provides the same critical information 
to all subjects and documents the provision of it for legal purposes. In addition, if 
presented to subjects during the baseline visit, the tutorial is a prudent use of the 
subject’s waiting time, which is a concern in this study where this first research 
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visit can last up to four hours. This is also a risk as the use of this program has 
the potential to diminish an aspect of relationship building and trust that evolves 
before and during the informed consent process. Rosoff (1999) noted that the 
personal bond between the physician and subject/patient, which has been 
considered an essential element of the therapeutic relationship, may be 
weakened by the use of computerized information disclosure devices. As 
subjects/patients become better educated, the nature of the relationship 
becomes more collaborative; however, there is a tendency when a transaction is 
routinized and reduced to a ritual, for the ritual to stifle dynamic human 
interaction. It is important that this is not overlooked because a subject may 
begin, but may not continue to participate in a study that offers no direct benefit 
to him, unless there are some interpersonal and/or social reasons for doing so.  
In trying to incorporate all of these elements into the tutorial, differences of 
opinion among the design team emerged. Dr. Dornfeld suggested that repetition 
is useful in conveying such specific information whereas Dr. Snyder expressed 
concern that the tutorial was too long and repetitive. Everyone was interested in 
selecting the photos and graphics. As the tutorial is graphics based, it was 
believed to be important to include the appropriate representation of men and 
health care providers in the pictures and video clips. This meant including men in 
the entire age range, of all races, professions and lifestyles. (The present photos 
are those that were freely available and will be replaced before the tutorial is 
produced.) The graphic elements could add impact by streaming video of a 
physician explaining the complex aspects of the study such as the study design, 
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placebo and risks. Providing a message from a familiar authority figure was 
believed to enhance the credibility of the content. The video clips could also 
include men as subjects demonstrating a procedure such as stair climbing, as 
subjects have reported that they find such clips useful (Agre, 2003). Ultimately 
the richness of the media will be balanced by the cost. 
It is worth noting that not only will the subject matter experts have different 
reactions to the tutorial but that the users will also have diverse opinions about 
the content. The original objective was to develop a tutorial that would be more 
informative for participants than the traditional text method; as such, it will be 
important to include a step in the development process that incorporates the 
feedback of these stakeholders in the design process.    
Dr. Dornfeld and I discussed the “Check Your Understanding” sections 
and how they can be most useful, given the static nature of the media and the 8th 
grade reading level requirement. The Flesch Kincaid Grade Level score of the 
tutorial is 7.6, which is equivalent to a reading level between 7th and 8th grade. 
The Flesch Kincaid Grade Level Score is a measure based on the number of 
words per sentence and the number of syllables per word (Flesch Kincaid 
Readability Score, 2008). Initially, the tutorial had two questions per module as I 
tried to avoid asking questions in which the responses were a simple return of 
facts just learned. Dr. Dornfeld urged me to examine what I was trying to achieve 
in asking these questions; is it important for subjects to answer them correctly or 
to serve as an indicator of level of understanding? As the long-term objective was 
to test this method for improving understanding of informed consent rather than 
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to rely on the paper document only, the responses should serve as an indicator 
of understanding associated with each module. He pointed out that many 
important aspects of the study were presented in each module and that this is the 
only opportunity in the process to evaluate what a subject knows at this point in 
time. He suggested that I develop additional questions for each module as they 
can serve, at a minimum, as a way  to demonstrate that a subject has paid 
attention. Additional post-test questions could be developed and administered at 
a subsequent research visit, one or three months later, for example, that could 
serve as measures of information retention. Dr. Snyder was concerned about 
asking so many questions of subjects during the tutorial and thought that this 
could be an obstacle to some subjects. We agreed to include all of the questions 
and to conduct a formal pilot test and focus group to learn more about each 
subject’s reaction to the number and content of the questions. Dr. Dornfeld also 
recommended that the tutorial include guidelines with the output that would direct 
the person administering the informed consent process to review the topic areas 
that are not clear to the user. Early evaluation (during pilot testing of the tutorial) 
of the number and content of incorrect responses will help to revise the tutorial to 
meet the needs of the users.   
As an endocrinologist, Dr. Snyder focused on presenting the medical 
content clearly and succinctly. He concentrated on the prostate cancer risks of 
the study as they are the most difficult to convey because they assume some 
knowledge about prostate cancer and its risk factors, non-specific symptoms, 
and the approaches to treatment that the medical community endorses (The 
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University of Texas, M.D. Anderson Cancer Center, 2008). The pilot data indicate 
that these issues are cloaked in some level of anxiety by men. The safety 
monitoring for prostate cancer that is included in the Testosterone Trial is more 
vigilant and conservative than is the standard medical practice, which is a fact 
that may not be apparent to subjects. To explain these distinctions may require 
providing additional information about prostate cancer; however, this may 
heighten fears about prostate cancer that may or may not be warranted. This is a 
complex issue that the investigators have been struggling with at every phase of 
the proposal and is under discussion with the sponsor and the scientific review 
committee. Yet, our obligation in the informed consent process is to fully disclose 
all risks to the subject and this may require providing supplemental information. 
Figure 2 depicts the prostate cancer risk section of the tutorial. 
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Figure 2. Risks and Benefits Module: Prostate Cancer Risk 
Prostate cancer
  
There could be small areas of cancer in the 
prostate that are not harmful and are not 
causing a health problem to you now. Using 
testosterone could change these small prostate 
cancers that are not harmful, into harmful ones. 
 
Presently, there is not enough information to 
know for certain about the effects of taking 
testosterone on prostate cancer.  
 
You will have rectal exams to check your 
prostate, and blood tests to learn your PSA 
result, which is the prostate cancer blood test. 
You will be asked questions about your prostate 
health and medical history.  
 
Your prostate and the risk of developing 
prostate cancer will be monitored closely over 
the course of the study. Regular screening such 
as the kind you will receive in this study, helps 
detect prostate cancer in its early stages. 
 
Dr. Fromell focused on the essential elements of the informed consent 
document as they are represented in the tutorial. Because of several recent 
instances of loss of research data in NIH and Veteran’s Administration studies, 
there is heightened interest by universities and sponsors about issues of data 
privacy and the disclosure of Protected Health Information (PHI), the individually 
identifiable health information such as name, address, medical history and 
medical record number (HIPAA Privacy Rule, 2007). All informed consent 
documents and any information provided to subjects as informed consent tools 
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such as this tutorial, must describe how these data will be protected, how they 
may be used and to whom they may be disclosed. The institution must not use 
vague statements such as “every effort will be made to protect your personal 
information;” rather we must strive to be as specific as possible in describing how 
confidential data will be protected. This can be confusing and worrisome to 
subjects. Figure 3 depicts the section of the tutorial that describes protection of 
confidential information.  
Figure 3. Risks and Benefits Module: Confidential Health Information 
Will confidential health information be collected as part of this study? 
Some private information about your health will be collected like your medical history, 
and your answers to questions about your physical function, sexual function, and 
other questionnaires.  
All information (including blood samples) collected in this study is kept strictly private 
by using study code numbers to collect information instead of names.  
This code number will be on the blood samples, questionnaires and in the 
computer that saves your responses.   
Your contact information will be locked securely in files at the 
research clinic and used only by the staff to contact you.                    
                                                                                         
The information collected in the study is saved in a highly secure computer system. 
Only those people who are working to analyze the information will be able to view it.  
  
Authorized study representatives may review and copy data collected from 
this study and your medical records. Your name will never appear in 
any articles that are published of the results from this research.                     
 
In order to advance this tool to the implementation stage, Dr. Dornfeld 
recommended that I write a development proposal to accompany the tutorial that 
describes the scope of work for the production phase. This was completed and is 
presented in Appendix C, Multimedia Tool Development Proposal. It includes 
information about who will be responsible for the content, description and 
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expectations of the incorporated technology, and the review and approval 
process. He urged me that the production process should not begin until such 
information is written and clarified.   
The content and format of the Testosterone Trial tutorial will remain stable 
for a brief time. The next phase will be review and revision by a larger group of 
physicians and researchers from among the 18 Testosterone Trial Research 
Network clinical sites who will evaluate it based on their institutional requirements 
and the needs of their local study populations. In order to evaluate this aspect of 
the tutorial it will be pilot tested in several research centers. This is an important 
step as the clinical sites differ widely, from an upper-middle class San Diego, 
California suburb to downtown Birmingham, Alabama. The tutorial will ultimately 
be reviewed by the Institutional Review Board of each participating medical 
center. 
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CHAPTER 5 
CONCLUSION 
The informed consent process is an imperfect one as it is dependent on 
many variable human factors. Yet, it is a pivotal element of clinical research; 
without human volunteers, advances in medicine would be very limited and much 
riskier. Research practitioners have a responsibility to ensure that participation in 
research is informed and voluntary. This implies that we should strive to improve 
the effectiveness of informed consent methods.  
The scientific literature consistently reveals evidence of impaired 
understanding of informed consent information in older subjects and those with 
less formal education (Sugarman, McCrory, Hubal, 1998). This is an important 
consideration for the Testosterone Trial. The men in the trial will be 65 years and 
may have some health problems and age-associated memory impairment. The 
Testosterone Trial informed consent document is lengthy (17 pages), yet it still 
may not be adequately explaining important issues such as prostate cancer risk. 
It is difficult to reduce complex medical problems and research procedures to a 
few written paragraphs, while simultaneously acknowledging that there are still 
many aspects of testosterone use and risk that are unknown.  
What can be expected of people to know about the Testosterone Trial in 
order to make an informed choice, and how should it be measured? For informed 
consent to be meaningful, research subjects deserve to have all of their 
informational needs regarding a proposed intervention met. A growing body of 
literature shows that decision aids such as multimedia tools can influence 
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subjects’ decisions and improve satisfaction with research participation, and it is 
almost certain that as technology weaves its way into all aspects of daily living 
that such tools are here to stay (Rosoff, 1999).  
The next step to developing and implementing this tutorial is to present it 
to the research network investigators for final review and revision of content, 
pictures and graphics. After the final product is reviewed and approved by the 
Institutional Review Board at the University of Pennsylvania, it will likely be 
developed as a multimedia tool. During the pilot phase of the trial, I propose to 
conduct a pilot study of the informed consent process. The design will be a three-
armed study to measure differences in subject reactions among those who read 
the paper informed consent document only; those who use the multimedia tool 
only; and those who use the paper document and multimedia tool. The study will 
include pre- and post-testing phases and follow-up testing at 3 and 12 months. 
The tests will aim to discern differences between the three groups in terms of 
ability to answer specific questions about the research purpose and risks as well 
to accurately describe the study. It may be feasible to conduct focus groups with 
subjects who complete the study to discuss the reality of study participation 
compared to the initial description presented during the informed consent 
process.  
There is little research about the research process. As a result, 
established methods for conducting a study of this type are not available. I will 
examine the preliminary data and evaluate the process early during the pilot 
study to further develop and refine the methods. I will seek collaboration with the 
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Penn Office of Human Research, as they are the subject matter experts and 
thought leaders in the development of informed consent materials. I expect that 
this study will provide information about whether understanding of informed 
consent can be improved with educational interventions.   
Future research in this area could assess the optimum length and content 
of multimedia tools; feasibility and acceptability of this media; and legal and 
ethical implications of using multimedia instead of written text for obtaining 
informed consent. The publication and presentation of the results will inform 
researchers about the utility and benefits of advanced technology approaches to 
the informed consent process. The organizational changes that would have to 
occur in order for this process to gain acceptance in the medical research 
community will be formidable. It will require an extensive communication plan to 
show that such a process change is advantageous to researchers as well as an 
improvement for subjects.  
As clinical trials continue to evolve, becoming increasingly large, 
decentralized and global, it is important to maintain the fundamental human 
principals of autonomy and self-determination. As the shapers of medical care 
and public health, researchers are obligated to strive to improve the human 
aspects of the medical research process as well as the scientific ones, and to 
seek innovative and informative ways to benefit the citizens who participate.  
Gaining truly informed consent should be the objective of the process, not merely 
meeting the letter of the law.  
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Slide 1 
Testosterone Trial 
Research Informed Consent 
Education Program
Denise Cifelli 
Capstone 705
May 2, 2008
 
 
Slide 2 Instructions
 
NOTE: This slide will explain the functionality that 
is incorporated into the tutorial and will describe 
the features (using audio and video) that are 
included in the modules such as the table of 
contents, navigation buttons, mouse-over 
information and the Check Your Understanding 
sections.  
Slide 3 
Table of Contents 
• Introduction
• Participating in the Trial 
• 4 Testosterone Trials in 1
• Tests and Procedures
• Risks and Benefits
• More Important Information
• Summary
 
 
Slide 4 
Introduction
This tutorial includes information about the 
Testosterone Trial, not specific medical 
advice.
The pictures have been included to 
improve your understanding.
If you have questions, please write them 
down and ask the doctor or someone from 
the research team.
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Slide 5 
Welcome to this education program 
about the Testosterone Trial 
Research Study.
The Testosterone Trial is sponsored 
by the National Institutes of Health 
and Solvay Pharmaceuticals.
 
 
Slide 6 
This program will explain the Testosterone 
Trial to you so that you can decide if you 
are interested in taking part. 
The Testosterone Trial is being conducted 
by doctors and nurses at your health 
center and around the United States to 
study how using testosterone affects 
men’s health. 
 
 
Slide 7 
The information in this  
program accompanies the 
consent form that you were 
given to read. 
This education program 
was made to provide clear 
explanations of the study 
details to help you better 
understand the study and 
make an informed choice 
about participating. 
 
 
Slide 8 
Experienced doctors, 
nurses and members 
of their research 
teams will conduct 
this research study at 
18 medical centers in 
the United States. 
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Slide 9 
Boston, MA
New Haven, CT
Hartford, CT
New York City, NY
Baltimore, MD
Washington, DC
Gainesville, FL
Minneapolis, MN
Chicago, IL
Pittsburgh, PA
Birmingham, AL
Houston, TX
Galveston, TX
Seattle, WA
Portland, OR
Palo Alto, CA
Los Angeles, CA
San Diego, CA
Testosterone Trial Network Map
 
Audio - These are the 18 medical centers that are 
part of this research study. 
Slide 10 
This is a research 
study about men, age 
65 and older, using 
testosterone.
Your regular doctor 
will continue to work 
with you to manage 
your medical care.
 
 
Slide 11 
As people age, they change in 
many ways which are part of 
the normal aging process. 
They may have difficulty 
walking, less interest in sex, 
difficulty remembering and  
less energy.  
When men get older, the 
amount of testosterone, the 
main male hormone, gets 
lower. It is possible that low 
testosterone could be a cause 
of these changes.  
 
 
Slide 12 
The goal of this study is to 
find out if older men who 
take testosterone will have 
improvement in walking, 
be more interested in sex, 
improvement in memory 
and an improved energy 
level.  
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Slide 13 
The 4 areas of 
research in this study 
are….
• Physical Function
• Sexual Function
• Memory
• Energy
 
 
Slide 14 
Physical
…is focused on 
walking, climbing 
stairs, moving 
around safely and 
doing daily 
activities.
 
 
Slide 15 
Sexual
…is focused on your 
interest in sex and 
your ability to have 
sex, as well as 
your thoughts and 
feelings about sex. 
 
 
Slide 16 
Memory
…is focused on your 
memory for 
information that your 
hear, information 
that you read to 
yourself, and other 
tests of your mental 
ability.
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Slide 17 
Energy
…is focused 
feelings of 
tiredness, energy 
level, moods and 
emotional states.
 
 
Slide 18 
Check Your Understanding
The study will be conducted in 
men under age 65.
When men get older, their 
testosterone level decreases.
 True
 False
 True
 False
 
A mouse-over feature will be used in the 
checkboxes to explain which answers are correct 
and incorrect, including a brief explanation.  
Check Your Understanding Statement:  
The study will be conducted in men under age 65. 
True. Incorrect. The study will include men who 
are 65 and older. 
False. Correct. The study will include men who are 
65 and older. 
Check Your Understanding Statement:  
When men get older, their testosterone level 
decreases. 
True. Correct. As men age their testosterone level 
decreases over time.  
False. Incorrect. As men age their testosterone 
level decreases over time. 
Slide 19 
Check Your Understanding
This is a study of how 
testosterone affects your…..   
(Choose one)
 a.  Walking, sexual interest, 
reading ability, energy
 b.  Walking, sexual interest, 
memory, relationships
 c.  Walking, sexual interest, 
memory, energy
Check your 
answer 
here. 
a. □
b. □
c. □
 
Check Your Understanding Statement:  
This is a study of how testosterone affects your.... 
a. Incorrect. The study will look at the effect of 
testosterone on walking, sexual interest, memory, 
energy 
b. Incorrect. The study will look at the effect of 
testosterone on walking, sexual interest, memory, 
energy 
c. Correct. 
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Slide 20 
Participating in the Trial
 
 
Slide 21 
What will happen in this study?
During this research study, men will take 
testosterone for 1 year. Men will 
participate in research visits by answering  
questionnaires and performing tests. 
When the study is over, doctors will know 
a great deal more about the effects of 
testosterone, and if it improves men’s 
health and well-being.  
 
 
Slide 22 
Voluntary Participation
Taking part in this research 
study is voluntary. You do 
not have to take part in it if 
you do not want to. 
If you do take part, you can 
leave at any time. 
If you decide not to take 
part, your medical care will 
not be affected in any way. 
 
 
Slide 23 
Qualifying to be in the study is 
based on …. 
• Age - 65 years or older
• Testosterone level between 100 and 250
• Symptoms you report
• Your medical history 
• Answers to questionnaires
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Slide 24 Why are you being asked to take part 
in this study?
You are being asked to take part in this 
study because you are 65 or older and 
your testosterone level is low. This 
information was found when your blood 
was tested at the previous visits. 
The questions that you answered show 
that you have some of the signs and 
symptoms of aging that low testosterone 
might cause. 
You have been asked to read this consent 
form and consider being in the study 
because you seem to be a good match for 
the study. 
 
 
Slide 25 What is the purpose of this 
research study?
Testosterone is a hormone 
produced by your body.  
The amount of this hormone 
decreases with age. 
The main goal of this study is to 
find out if using testosterone 
improves walking, sexual 
interest and function, memory, 
and energy in men your age. 
 
 
Slide 26 How long will you be in this 
research study?
If you decide to take part, you will be in the study for 2 
years. 
In the 1st year, you will take testosterone or a placebo. 
In the 2nd year, you will not take testosterone, but will 
continue to be in the study.  
Year 2
Follow-up Phase
(12 months) 
Year 1 
Testosterone Treatment Phase
(12 months) 
 
 
Slide 27 
During the 1st year, you will come to the research clinic 
for 7 visits and you will be called by the research team 
6 times for information. The chart below shows 
when those visits will happen.
*This visit is called the Baseline Visit.
C = Research Clinic visit in person;  P = Phone contact
PPPPPP CCCCCCC
1211109876543210*
Year 1 
Testosterone Treatment Phase
(In Months) 
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Slide 28 During the 2nd year, you will come to the research 
clinic once and answer questions by 
telephone once.                       ↓
C = Research Clinic visit in person;  P = Phone contact
PCCPPCPPCPPCCCC
24181211109876543210
Year 2
Follow-
up 
Phase
Year 1 
Testosterone Treatment Phase
(In Months) 
 
 
Slide 29 
Check Your Understanding
If you take part in the 
study, you have to stay 
in it for 2 years.
Accurately reporting 
your medical history is 
important to the study.
 True
 False
 True
 False
 
Check Your Understanding Statement:  
If you take part in the study, you have to stay in it 
for 2 years. 
True. Incorrect. If you start the study and do not 
want to finish it, you may stop when you want.  
False. Correct. If you start the study and do not 
want to finish it, you may stop when you want.  
Check Your Understanding Statement:  
Accurately reporting your medical history is 
important to the study. 
True. Correct. It is important to provide accurate 
information about your past and present health 
conditions. 
False. Incorrect. It is important to provide accurate 
information about your past and present health 
conditions. 
Slide 30 
Check Your Understanding
Testosterone is a 
male hormone that 
decreases with age.
You are being 
asked to participate 
in this study for …
 True
 False
 6 months
 1 year
 2 years
 
Check Your Understanding Statement: 
Testosterone is a male hormone that decreases 
with age. 
True. Correct. As men age it is normal for 
testosterone, the main male hormone, to 
decrease.   
False. Incorrect. As men age it is normal for 
testosterone, the main male hormone, to 
decrease. 
Check Your Understanding Statement:  
You are being asked to participate in this study for 
6 months. Incorrect. You will participate in the 
study for a total of 2 years. 
1 year. Incorrect. You will take testostereone for 1 
year but will participate in the study for a total of 2 
years.  
2 years. Correct. 
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Slide 31 
4 Testosterone Trials in 1
 
 
Slide 32 
What is involved in this research 
study?
This study involves using testosterone or a 
placebo for one year in the form of a gel applied 
to the skin. The tests that you take and 
questions that you answer will show what 
changes, if any, happen.
The questionnaires that you answered were 
done to find out which of the 4 areas of study 
match what you reported about your health. 
 
 
Slide 33 
You could be in one or 
more of the 4 separate 
studies, called trials. 
For the trials in which you 
qualify, you will take part 
in those that you choose.  
The four trials are focused 
on:  
– Physical Function 
– Sexual Function 
– Memory
– Energy 
 
 
Slide 34 
Physical Function
…..is about how well you 
get around physically 
in terms of walking 
and moving around. 
This trial measures 
walking speed, stair 
climbing, and asks 
questions about 
physical activity. 
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Slide 35 
Sexual Function
…..is about your interest in 
sex and your ability to 
have sex. This trial asks 
for information about your 
sexual function and 
thoughts. 
 
 
Slide 36 
Memory
…..measures memory 
of information you 
have heard, written 
information and 
several other tests of 
your mental ability 
such as your 
memory of designs 
and drawings. 
 
 
Slide 37 
Energy
…..asks about your 
energy level, moods, 
depression and 
quality of life.
 
 
Slide 38 
What does study assignment mean?
You will be in one of two 
groups. One group will be 
given testosterone gel. The 
other group will be given a 
matching placebo gel, which 
does not contain testosterone. 
Study assignment means being 
put in one group or the other. 
A computer program will select 
the group that you are in.    
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Slide 39 Placebo
A placebo is a substance that is 
made without the active ingredient, 
but looks like the “real thing.” The 
testosterone and placebo gels will 
be in identical pump bottles. The 2 
gels will look, feel and smell exactly 
the same. 
No one who is working on the 
study (the doctors, nurses, staff or 
you) will know which group you are 
in. This is done so that everyone is 
treated the same, without different 
expectations of how you might 
answer questions or perform in 
tests. 
Testosterone Placebo
 
 
Slide 40 
How do you take testosterone?
You will apply a specific 
amount of testosterone gel 
directly on your chest, 
stomach or upper arms once 
a day, every day for a year. 
You will be shown how to do 
this so that you use the 
correct dose of gel. 
 
 
Slide 41 
The amount of gel 
that you get from the 
pump bottle will be 
prescribed. This is the 
dose of testosterone 
that you will be using. 
You should not use 
more or less than this 
dose.
 
 
Slide 42 
It is important to wash your 
hands after putting on the gel. 
You must then let the gel dry 
and cover up your chest with 
a shirt before having any 
physical contact. 
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Slide 43 
Blood will be drawn to 
check your testosterone 
level each time you 
come to a research 
clinic visit. 
If a dose change is 
needed, you will be told 
exactly what to do. 
 
 
Slide 44 
Check Your Understanding
It does not matter how much 
gel is used when applying 
testosterone gel.
Blood will be drawn at each 
research clinic visit to check 
the testosterone level.
 True
 False
 True
 False
 
Check Your Understanding Statement:  
It does not matter how much gel is used when 
applying testosterone gel. 
True. Incorrect. The amount of gel applied to the 
skin is the prescribed dose of testosterone that 
should be used.  
False. Correct. The amount of gel applied to the 
skin is the prescribed dose of testosterone that 
should be used. 
Check Your Understanding Statement:  
Blood will be drawn at each research clinic visit to 
check the testosterone level. 
True. Correct. Blood will be drawn at each visit to 
check testosterone level as well as several other 
tests.  
False. Incorrect. Blood will be drawn at each visit 
to check testosterone level as well as several 
other tests. 
Slide 45 
Check Your Understanding
Study assignment means 
that….
(Choose one.)
a. A computer will calculate 
your testosterone level.
b. You will be put into one of 
two groups.
c. There will be additional 
reading to do for the study.
Check your 
answer 
here. 
a. □
b. □
c. □
 
Check Your Understanding Statement:  
Study assignment means that…. 
a. Incorrect. Study assignment means that you will 
be put into one of two groups.  
b. Correct. 
c. Incorrect. Study assignment means that you will 
be put into one of two groups. 
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Slide 46 
Check Your Understanding
The study doctors and nurses will 
choose which group you are 
assigned to.
After applying the gel, you should 
wash your hands and cover the 
skin so that others do not touch 
the gel.
 True
 False
 True
 False
 
Check Your Understanding Statement:  
The study doctors and nurses will choose which 
group you are assigned to. 
True. Incorrect. The group that you are in 
(testosterone or placebo) will not be chosen by 
anyone in the research study. A computer will 
make the study assignment.  
False. Correct. The group that you are in 
(testosterone or placebo) will not be chosen by 
anyone in the research study. A computer will 
make the study assignment. 
Check Your Understanding Statement:  
After applying the gel, you should wash your 
hands and cover the skin so that others do not 
touch the gel. 
True. Correct. Even after the gel dries on your 
skin, you must wash your hands and cover the 
skin so that others do not come into contact with 
the testosterone on your skin.  
False. Incorrect. Even after the gel dries on your 
skin, you must wash your hands and cover the 
skin so that others do not come into contact with 
the testosterone on your skin. 
Slide 47 
Check Your Understanding
In this study, the placebo is…
(Choose one.)
a. A pill
b. A gel with a different 
medication than 
testosterone
c. A gel that will seem identical 
to testosterone gel but will 
not have testosterone in it
d. A device
Check your 
answer here. 
a. □
b. □
c. □
d. □
 
Check Your Understanding Statement: 
 In this study, the placebo is… 
a. Incorrect. In a different study of oral medication 
it could be a pill, but in this study testosterone is 
being given as a gel that is applied to the skin, not 
a pill taken by mouth. 
b. Incorrect. In this study the placebo is a gel that 
will seem identical to testosterone gel but will not 
have testosterone, or any other medication, in it. 
c. Correct. 
d. Incorrect. A device is not being used in this 
study. 
Slide 48 
Tests and Procedures
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Slide 49 The following things will happen 
at each visit….
• Your height, weight, waist, 
hips and blood pressure will 
be measured
• Your blood will be drawn (2 
tubes, which is about 3 
tablespoons)
• How far you walk in 6 minutes 
will be measured
• A rectal exam to check the 
size of your prostate and for 
the presence of nodules will 
be done (at Months 3 and 12)
 
 
Slide 50 
You will be asked about ….
• the medicines that you take 
(prescription and over-the-
counter drugs and herbal or 
supplements) 
• health events, by asking you 
to describe new health 
problems that you have or 
changes to conditions that 
you already have. You will be 
asked if you had a heart 
attack or stroke, but should 
report all of your health 
problems.  
 
 
Slide 51 
You will be asked about ….
• trouble urinating
• difficulty doing 
ordinary things like 
washing up in the 
morning or grocery 
shopping
 
 
Slide 52 
You will be asked about ….
• any falls you may 
have had and what 
happened
• your memory, and 
you will do tests to 
see what you 
remember
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Slide 53 
You will be asked about ….
• depression and 
moods
• your interest in sex
• your feelings of 
energy and tiredness
 
 
Slide 54 
You will be asked to….
• respond to a few questionnaires 
at home using a phone system 
that lets you answer questions in 
the privacy of your home (or 
anywhere).
• The sexual diary, tiredness, 
depression and mood 
questionnaires will be done at 
home using this system. 
• You will be taught how to use 
this phone system, called IVR, 
by the research staff. 
 
 
Slide 55 
What is Interactive Voice Response (IVR)?
IVR is a computer based phone 
response system. You may have used 
a similar system when calling the gas 
or electric company. 
Recorded messages will guide you 
through the steps of answering the 
questions. You will use the phone 
number pad to answer them. 
Your answers will be stored in an 
electronic computer file by your study 
code number. Your voice will not be 
recorded. 
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Slide 56 
Check Your Understanding
A rectal exam is being 
done to check for colon 
cancer. 
It is not important to report 
changes in health 
conditions like diabetes, 
since it is not related to 
taking testosterone. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
A rectal exam is being done to check for colon 
cancer.  
True. Incorrect. A rectal exam is being done to 
check for prostate enlargement and the presence 
of nodules in the prostate.  
False. Correct.  A rectal exam is being done to 
check for prostate enlargement and the presence 
of nodules in the prostate. 
Check Your Understanding Statement:  
It is not important to report changes in health 
conditions like diabetes, since it is not related to 
taking testosterone.  
True. Incorrect. All of the changes in your health 
status are important to report. This may be 
informative about what is happening to all of the 
men in the study.  
False. Correct. All of the changes in your health 
status are important to report. This may be 
informative about what is happening to all of the 
men in the study. 
Slide 57 
Check Your Understanding
You will be asked to report 
all of the medicine that 
you take, even over-the-
counter medicines.
You should not report 
trouble urinating because 
that happens to most men, 
as they get older.   
 True
 False
 True
 False
 
Check Your Understanding Statement:  
You will be asked to report all of the medicine that 
you take, even over-the- counter medicines.  
True. Correct. It is important to report as 
accurately as possible all of the medicine that you 
take, even over the counter medicines.  
False. Incorrect. It is important to report as 
accurately as possible all of the medicine that you 
take, even over the counter medicines.  
Check Your Understanding Statement:  
You should not report trouble urinating because 
that happens to most men, as they get older.    
True. Incorrect. You should report any problems or 
changes that happen to the way you urinate. 
False. Correct.  You should report any problems or 
changes that happen to the way you urinate. 
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Slide 58 
Check Your Understanding
You will respond to 
questions using the IVR 
system by….
a. Speaking slowly so your 
voice can be recorded 
b. Using the number pad on 
the phone
c. Using a computer to go 
to a website
Check your 
answer here. 
a. □
b. □
c. □
 
Check Your Understanding Statement:  
You will respond to questions using the IVR 
system by…. 
a.  Incorrect. Your voice will not be recorded in the 
IVR system. 
b. Correct. You will use the number pad on the 
phone to answer questions. 
c. Incorrect. It is not necessary to use a computer 
to answer these questions. You will use the 
number pad on the phone to answer questions. 
Slide 59 
Risks and Benefits
 
 
Slide 60 
What are the risks of this study?
There is a chance that using testosterone 
may make some conditions worse. You 
will be checked for these before and 
during the study.
The risks that you should understand are 
described in the following slides:  
 
 
Slide 61 
Prostate cancer
There could be small areas 
of cancer in the prostate that 
are not harmful and are not 
causing a health problem to 
you now. Using testosterone 
could change these small 
prostate cancers that are not 
harmful, into harmful ones. 
Presently, there is not 
enough information to know 
about the effects of taking 
testosterone on prostate 
cancer. 
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Slide 62 
You will have rectal exams to check 
your prostate, and blood tests to 
learn your PSA result, which is the 
prostate cancer blood test. You will 
be asked questions about your 
prostate health and medical history. 
Your prostate and the risk of 
developing prostate cancer will be 
monitored closely over the course 
of the study. Regular screening 
such as the kind you will receive in 
this study, helps detect prostate 
cancer in its early stages. 
 
 
Slide 63 
Benign Prostatic Hyperplasia (BPH)
BPH is the condition of having an 
enlarged prostate gland. Using 
testosterone may increase the size of 
the prostate, which could cause a 
decrease in urine flow. 
You may see this as difficulty in starting 
and finishing when you urinate.
Presently there is not enough 
information to know about the effects of 
taking testosterone on BPH. You will be 
checked for this condition throughout the 
1st year. The research team will act on 
changes that you report by referring you 
to the study urologist.
 
 
Slide 64 
High red blood cell count
Testosterone normally increases 
the number of red blood cells, which 
is why men have higher red blood 
cell counts than women.  
It is possible that using testosterone 
could increase the number of red 
blood cells that you have to higher 
than normal. This might increase 
the chance of stroke.  
During the 1st year, your blood 
count will be checked frequently. 
Increases above normal will be 
investigated. You may be told to 
use less gel or you may be told to 
stop using the testosterone gel 
altogether.  
 
Slide 65 
Sleep apnea
Testosterone may increase the risk 
of sleep apnea, a condition in which 
not enough oxygen gets into the 
blood during sleep. This may result 
in excessive daytime sleepiness. 
The connection between 
testosterone and sleep apnea is not 
known, so you will be asked about it 
regularly. 
If you have been told that you have 
sleep apnea you can be in the study 
only if you are being treated for it. 
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Slide 66 
There is some risk in doing 
the study tests. It may be 
hard for you to do the 
walking test or climb the 
stairs. The study staff will be 
there to assist you at all 
times, but you can rest or 
stop at any time. 
 
 
Slide 67 
Having blood taken from 
you has a small risk of 
temporary mild pain, 
bruising or infection. It is 
possible that you could faint. 
There will be trained 
technicians to draw your 
blood. 
 
 
Slide 68 
You may feel it is hard to 
answer some questions 
because they are so 
personal. 
All of your answers are 
considered private and will 
not be shared with anyone. 
The information that you give 
will be given a code number. 
Your name or other personal 
information will not be 
connected to your answers. 
 
 
Slide 69 
You may find that the 
memory tests are tiring. 
You should just try to do 
the best you can. 
There are no passing or 
failing grades on these 
tests, and you should not 
practice taking these 
tests at home to do 
better.
 
 
V1.20080627 
Testosterone Trial Informed Consent Education Program - Appendix A  
 
63
Slide 70 Using Testosterone Safely
There are safety precautions 
that you must follow when 
using testosterone gel. 
You must be careful not to 
allow others to touch the gel on 
your skin. 
It is important to wash your 
hands, allow the gel to dry 
completely after you put it on, 
and to keep the skin covered.   
 
 
Slide 71 
If a prostate biopsy is 
needed, there are risks of 
bleeding and infection. You 
will be given detailed 
instructions before the 
procedure to reduce these 
possibilities. 
 
 
Slide 72 
Lastly, there is a chance that there are side 
effects that are not yet known.  
 
 
Slide 73 
Benefits
You may not get any benefit 
from being in this study. You 
may feel better or stronger, or 
you may not. 
By being in this study, you 
may help medical science 
gain a better understanding 
of testosterone treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
V1.20080627 
Testosterone Trial Informed Consent Education Program - Appendix A  
 
64
Slide 74 
Check Your Understanding
Changes in the prostate will be 
checked by measuring the PSA level 
in your blood, doing a rectal exam 
and asking questions about 
urinating.
Testosterone may cause an increase 
in the number of red blood cells. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
Changes in the prostate will be checked by 
measuring the PSA level in your blood, doing a 
rectal exam and asking questions about urinating. 
True. Correct. Measuring the PSA level in your 
blood, doing a rectal exam and asking questions 
about urinating are procedures that monitor you for 
changes in your prostate cancer risk and 
enlargement of your prostate. 
False. Incorrect. Measuring the PSA level in your 
blood, doing a rectal exam and asking questions 
about urinating are procedures that monitor you for 
changes in your prostate cancer risk and 
enlargement of your prostate. 
Check Your Understanding Statement: 
Testosterone may cause an increase in the 
number of red blood cells.  
True. Correct. Testosterone may cause an 
increase in the number of red blood cells. This 
may not occur, may be small or could be 
significant. This will be monitored over the course 
of the study and may require a change in the dose 
or discontinuation of testosterone gel.  
False. Incorrect. Testosterone may cause an 
increase in the number of red blood cells. This 
may not occur, may be small or could be 
significant. This will be monitored over the course 
of the study and may require a change in the dose 
or discontinuation of testosterone gel. 
Slide 75 
Check Your Understanding
Using testosterone will make 
you physically stronger.  
Using testosterone may enlarge 
your prostate gland. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
Using testosterone will make you physically 
stronger.   
True. Incorrect. It is not known for certain that 
testosterone will improve your physical strength.  
False. Correct. It is not known for certain that 
testosterone will improve your physical strength. 
Check Your Understanding Statement: 
Using testosterone may enlarge your prostate 
gland.  
True. Correct. It is possible that testosterone could 
make your prostate become enlarged. This may or 
may not happen to you.  
False. Incrrect. It is possible that testosterone 
could make your prostate become enlarged. This 
may or may not happen to you. 
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Slide 76 
Check Your Understanding
Using testosterone will cause 
you to have sleep apnea. 
You will have a prostate biopsy 
at the end of the study. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
Using testosterone will cause you to have sleep 
apnea.  
True. Incorrect. The connection between 
testosterone and sleep apnea is not clear. 
False. Correct. The connection between 
testosterone and sleep apnea is not clear. 
Check Your Understanding Statement:  
You will have a prostate biopsy at the end of the 
study.  
True. Incorrect. You will not automatically have a 
prostate biopsy at the end of the study. A prostate 
biopsy may be done if the prostate cancer risk 
signs (your PSA level and rectal exam) change. A 
urologist will determine if you should have a 
prostate biopsy. 
False. Correct. You will not automatically have a 
prostate biopsy at the end of the study. A prostate 
biopsy may be done if the prostate cancer risk 
signs (your PSA level and rectal exam) change. A 
urologist will determine if you should have a 
prostate biopsy. 
Slide 77 
More Important Information
 
 
Slide 78 
You will be paid a small 
amount of money, which 
will be given to you as you 
complete study visits. 
You will be reimbursed for 
travel expenses and 
parking. 
You will be given coupons 
for meals while you are at 
the research clinic visits.
Will you be paid for being in this 
research study?
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Slide 79 What if you want to leave the research 
study after you begin?
You can leave the 
study at any time. 
Dropping out of the 
study will not interfere 
with your future care.
 
 
Slide 80 Will confidential health information be 
collected as part of this study?
Some private information about your health will be 
collected like your medical history, and your answers to 
questions about your physical function, sexual function, 
and other questionnaires. 
All information (including blood samples) collected in this 
study is kept strictly private by using study code numbers 
to collect information instead of names. 
This code number will be on the blood samples and 
questionnaires and in the computer that saves your 
responses.  
Your contact information will be locked securely in files 
at the research clinic and used only by the staff to 
contact you.  
 
 
Slide 81 
The information collected in the study is saved in 
a highly secure computer system. Only those 
people who are working to analyze the 
information will be able to look at it. 
Authorized study representatives may review 
and copy data collected from this study and your 
medical records. Your name will never appear in 
any articles that are published of the results from 
this research. 
 
 
Slide 82 What will you do with the blood 
you collect?
Any blood that is left over after 
measuring testosterone, PSA and 
other tests will be saved at the 
Mayo Clinical Trial Services 
Central Laboratory for 5 years or 
more. 
These saved samples might be 
helpful in the future, if new tests 
are discovered that would enhance 
knowledge about testosterone. 
You will not be able to find out 
anything about these tests. 
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Slide 83 What happens if you are injured during 
the study?
If you are injured because of 
taking part in this research 
study, you should contact the 
study doctor or staff right away 
at the phone numbers provided 
on the front page of this form. 
They will advise you about 
what to do to next. 
 
 
Slide 84 What if you have questions about the 
study?
Your rights and protection as a 
research participant are very 
important. 
If you have any questions, concerns 
or complaints about this research 
study, or if you have questions about 
your rights as a research subject, feel 
free to contact the Principal 
Investigator listed on the front page of 
this form.  
You may also call your Institutional 
Office of Regulatory Affairs with any 
question, concerns or complaints. 
 
 
Slide 85 
Check Your Understanding
Blood samples that are taken for the 
study will be saved for several years.
To protect your personal information, 
the study will use study code 
numbers, secure computer 
technology and restrict access to 
study information to authorized 
personnel. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
Blood samples that are taken for the study will be 
saved for several years. 
True. Correct. Such samples may be useful for 
future research studies.  
False. Incorrect. Such samples may be useful for 
future research studies. 
Check Your Understanding Statement:  
To protect your personal information, the study will 
use study code numbers, secure computer 
technology and restrict access to study information 
to authorized personnel.  
True. Correct. Your personal information will be 
kept confidential.  
False. Incorrect. Your personal information will be 
kept confidential. 
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Slide 86 
Check Your Understanding
You will be paid a lump sum of 
money at the end of the study.
If you have a complaint about 
this research study, you may 
not contact anyone but the 
research study staff. 
 True
 False
 True
 False
 
Check Your Understanding Statement:  
You will be paid a lump sum of money at the end 
of the study. 
True. Incorrect. You will be paid as you complete 
certain research visits. Your travel expenses and 
meals will be provided. 
False. Correct. You will be paid as you complete 
certain research visits. Your travel expenses and 
meals will be provided. 
Check Your Understanding Statement:  
If you have a complaint about this research study, 
you may not contact anyone but the research 
study staff.  
True. Incorrect. Your rights as a research 
participant are very important. You may contact 
the investigator, staff, the office of regulatory 
affairs and/or research administration at this 
institution to discuss your concerns. 
False. Correct. Your rights as a research 
participant are very important. You may contact 
the investigator, staff, the office of regulatory 
affairs and/or research administration at this 
institution to discuss your concerns. 
Slide 87 
Check Your Understanding
If you start the study, it does 
not matter if you leave before 
you finish all of the research 
study visits.  
 True
 False
 
Check Your Understanding Statement:  
If you start the study, it does not matter if you 
leave before you finish all of the research study 
visits.   
True. Incorrect. You are free to leave the study at 
any time without effect to your healthcare. 
However, it is best to collect a complete set of 
information about your participation for the entire 
length of the study study whenever possible.  
False. Correct. You are free to leave the study at 
any time without effect to your healthcare. 
However, it is best to collect a complete set of 
information about your participation for the entire 
length of the study study whenever possible.  
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Slide 88 
Summary
 
 
Slide 89 
• The Testosterone Trial is being done to 
find out if older men who take testosterone 
will have improvement in walking, more 
interest in sex, improved memory and 
improved energy level.  
• There are 4 trials in this research study 
focused on:
• Physical Function
• Sexual Function
• Memory
• Energy
 
 
Slide 90 
If you decide to be in the study, you will ...
• be in the study for 2 years.
• use testosterone or placebo gel every day 
for 1 year. 
• go to 7 research clinic visits in the first 
year.
• report regularly about your health status 
and medicines.
• use an automated phone system to 
answer questions from home.
• be asked personal questions.
 
 
Slide 91 
During research clinic visits, you will …
• take a walking test.
• have your height, weight, waist, hips and 
blood pressure measured. 
• have blood drawn.
• have a rectal exam (at Month 3 and 12).
• be asked questions about physical ability, 
sexual interest, your memory and energy 
level.
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Slide 92 
You will be monitored for changes in …
• your prostate size and PSA. 
• your red blood count.
• how you urinate.
• how you sleep.
• other medical conditions that are new to 
you, and changes in those that you have 
known about.
 
 
Slide 93 
• There may be risks involved in taking 
testosterone that are not known.
• If you start the study and then decide to 
leave, it will not have an affect on your 
health care. 
• If you have concerns about your rights as 
a research participant, you may contact 
the investigator, research staff, and the 
office of regulatory affairs or research 
administration.  
 
 
Slide 94 
If you have questions or concerns…
Please discuss them with 
someone from the 
research team.
You may want to discuss 
this research study with 
your spouse or significant 
other as well as with your 
doctor. 
 
 
Slide 95 
Comments?
We appreciate your 
feedback!
If you would like to 
make comments 
about the tutorial, 
please do so by 
clicking the box on 
the right. 
 Write comments here.
____________________
____________________
____________________
____________________
____________________
____________________
____________________
____________________
____________________
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Slide 96 
Conclusion
Thank you for using this program 
and for considering participating in 
this research study. 
 
 
Slide 97 
Administrative Section
Tutorial management toolkit -
 View Check Your Understanding output.
 View Comments. 
 View audit trail.
 Check version control.
 
 
Slide 98 Sample Output –
Check Your Understanding             □ Printer Friendly
NAMore Important Information
Comments
NA – Not Applicable
Risks and Benefits
NATests and Procedures
4 Testosterone Trials in 1
NANANAParticipating in the Trial
NANANAIntroduction
Q6Q5Q4Q3Q2Q1Module
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INFORMED CONSENT DOCUMENT 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
Study Title:  The Testosterone Trial 
Main Study Consent Form 
P.I. Name and Department 
Co-P.I. Name(s) 
Telephone Numbers(s), 24-Hour Emergency Number 
IRB # of Protocol 
Sponsor: National Institute on Aging 
Invitation to Participate 
You are being invited to take part in a research study. The Testosterone Trial is a 
research study in men over the age of 65 who have a low blood level of the main male 
hormone, testosterone. This research study is being done to see if taking testosterone 
for one year will improve walking, sexual function, memory, and energy.  
This is a consent form. The information in this consent form will tell you about what will 
happen during the study and the possible risks and benefits, so that you can decide 
whether or not to participate. The form also includes other important information about 
the research study, including the health information we will collect. Please read this form 
carefully before deciding whether you want to take part. If there is anything you do not 
understand, please ask questions.   
Participation in this research study is voluntary. You do not have to take part in this 
study if you do not want to.  If you do take part, you can leave at any time. 
The National Institute on Aging (NIA) of the National Institutes of Health (NIH) and 
Solvay Pharmaceuticals are providing most of the funding for this study. This study will 
be conducted at 18 sites in the United States. The University of Pennsylvania, 
Philadelphia, PA, will manage the study. 
It is expected that 1200 men will take part in this study. Each man’s participation will last 
two years.   
Why am I being asked to take part in this study? 
You are being invited to take part in this study because you are 65 years of age or older 
and have complaints or symptoms that might be related to a low testosterone level.  
Testosterone is a hormone produced by the testes and is responsible for the 
development of normal male muscles, bone strength, energy level, and sexual function.  
In many men the amount testosterone in their blood gradually decreases with age.   
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Some research suggests that this fall in testosterone might cause some of the 
unwanted effects of aging. 
What is the purpose of this research study? 
The main purpose of this research study is to determine if taking testosterone improves 
walking, sexual function, memory, and energy levels of men with low testosterone.  
Other purposes are to find out if testosterone treatment improves the ability to perform 
daily activities, improves mood and lowers the tendency to fall. 
How long will I be in this research study? 
If you qualify, you will take part in the study for 2 years. During the first year you will 
receive treatment with testosterone or with a placebo, which looks like medication but 
does not have the active ingredient in it.  Also during the first year you will come to the 
research clinic for seven visits for different types of testing, and you will also answer 
questions from home by telephone.  During the second year you will come to the 
research clinic once and answer questions by telephone once.  
What is involved in this research study? 
The first step is to find out if you qualify to take part in the study. You will be eligible if 
your blood testosterone is low, if you have a problem that could be caused by low 
testosterone, and if you do not have a problem that testosterone treatment could make 
worse.  If you qualify for one or more of the four separate studies (called trials) that are 
part of this study, you will take part in the trials that you choose.  The four trials are 
called:  
 Physical Function Trial 
 Sexual Function Trial 
 Cognitive Function Trial 
 Vitality Trial 
You will be treated for one year. During this year you will be tested for the possible 
desirable and undesirable effects of testosterone. During the year after treatment, you 
will be followed to make sure that your general health remains good. The following 
sections describe the clinic visits, tests and procedures in this study.  
Eligibility  
The test results from Screening Visits 1 and 2 show that you qualify for one or more of 
the four separate trials. If you agree to participate, you will move to the next step and 
take a few more tests at the Baseline Visit at the research clinic.  
Study Treatment Assignment 
If you agree to participate, you will be assigned to one of two treatment groups.  One 
group will receive testosterone in a gel which is applied to the skin every day.  The other 
group will receive a matching placebo gel, which does not contain testosterone. (The 2 
gels will appear the same, but one will have testosterone in it and the other will not.) 
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You will be assigned to a treatment group by a computer program. Neither you, the 
study doctors, nor the study staff will know if you are assigned to the group that is 
treated with testosterone or the group that is treated with the placebo.  
How Will I Take the Treatment 
Testosterone gel and placebo gel both come in an upright tube with a pump on top.  
The gel is applied once a day. You will push down on the pump with one hand and will 
catch the gel (which is a combination of alcohol and water) in the palm of the other 
hand.  Both gels look, feel and smell the same.  You will then spread the gel on the skin 
of your abdomen, chest or upper arm.  After letting the gel dry, which usually takes 
about 2-3 minutes, you should wash your hands. You must cover the area where the gel 
is applied, because it is very important to keep the testosterone from touching anyone 
else. This is especially important for women or children, who might develop male 
features, such as facial hair, if they were exposed to testosterone.   
The Four Trials 
If you are eligible for more than one trial, you may choose to participate in only one trial 
or as many trials for which you qualify and are interested in.  Some tests will be given to 
all participants in the study.  Other tests will be given only to those who take part in a 
particular trial.  The following is an explanation of the tests used in each of the four 
trials. 
1.  Physical Function Trial:  We will measure how far you can walk in a certain period of 
time.  Another test is a measure of stair climbing. There are also questions about daily 
physical function.  
2.  Sexual Function Trial:   The tests in this trial will be questionnaires about your ability 
to have sex and erections.  One of them you will answer from home by telephone, and 
the others you will complete at the research clinic.  
3.  Cognitive Function Trial:  The tests in this trial will be about your memory, such as 
how well you can remember a paragraph that is read aloud to you by someone and how 
well you can remember designs and drawings.   
4.  Vitality Trial:  The test in this trial will be a questionnaire about your energy level that 
you will answer from home by telephone.  Other tests will be questionnaires about mood 
and emotional state that will be done at the research clinic.   
Description of Tests and Procedures  
The list below describes each test and procedure that will be done during the course of 
the study. The tests are grouped by those everyone will have, followed by tests that are 
only for those taking part in a specific trial.  
Interactive Voice Response (IVR) 
Some of the tests involve questionnaires.  Some of the questionnaires you will answer 
with paper and pencil at the research clinic, and others you will answer from home using 
a computer-based telephone system called IVR.  For IVR, recorded messages will 
guide you through the questions. You will answer the questions using the phone 
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number pad. Your answers will be kept in a secure computer file by a code number that 
cannot be traced back to your name or other private information.   
Tests for Everyone in All Trials  
Most of the tests and procedures will happen every 3 months when you come to the 
research clinic. The table on the last page shows what will happen each time you come 
to the research clinic and when we call you on the phone between visits.   
Blood Draw 
Blood will be taken once a month for the first 3 months and then every 3 months.  
Testosterone will be measured each time.  Prostate-specific antigen (PSA), a blood test 
for prostate cancer, will be measured at baseline, 3 and 12 months.  Hemoglobin (a test 
for red blood cells) will be measured every three months. 
Physical Measurements 
We will measure your height, weight, waist, hips and blood pressure.  
Rectal Exam 
This exam involves putting a gloved finger in the rectum, to feel for hardness or lumps in 
the prostate. It will be done at the 3 and 12 month visits.  
Walking Test 
You will be asked to walk for 6 minutes down a corridor at a normal pace. The distance 
you walk and how fast you walk will be measured.  
Your Medicine 
You will be asked to bring all of the medicines (prescription, over-the-counter and herbal 
or supplements) you are taking to the research clinic at each visit.  We will also ask 
about medicines during monthly phone calls.  
Health Problems and Changes  
You will be asked to describe new health problems that may have happened or changes 
to conditions that you already have at each visit and phone call. 
Urination Questions 
You will be asked a few questions about problems with passing urine.   
Activities of Daily Living 
You will be asked about difficulties in general activities of daily living, such as bathing or 
making lunch, as well during the previous month.  
Falls 
You will be asked if you have experienced a fall during the previous 3 months.   
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General Memory Test  
You will be asked questions that test your memory and thinking at baseline and at 12 
months.    
Memory Questions 
You will be asked 6 questions about your memory compared to when you were 
younger.  This test will be done at this screening visit in everyone and after 12 months 
in those participating in the Cognitive Function Trial. This test will take less than 5 
minutes. 
Memory for Words 
Two paragraphs will be read aloud to you by someone and you will be asked what you 
remember.  This test will be done every 6 months. 
Sex Diary  
You will be asked 6 questions about your sexual activity and feelings using the IVR 
phone system. This test will be done once a day for 7 days and repeated every 3 
months. 
Depression Questions 
You will be asked several questions about whether you feel depressed. You will use the 
IVR phone system to answer these questions.  
Good and Bad Mood Questions  
You will be asked questions that are about your mood.  You will use the IVR phone 
system to answer these questions.  
Tiredness Questions 
You will be asked questions about your energy level and tiredness. You will use the IVR 
phone system to answer these questions.  
Change in the Way You Feel  
You will be asked to compare how you feel now to how you felt at the start of the study.   
Tests for Participants in the Physical Function Trial Only- given every 3 months 
Stair Climbing Test 
You will be asked to climb a standard (12-step) staircase at your normal pace. 
Physical Function Questions  
You will be asked questions about how you can move and your physical abilities. 
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Tests for Participants in Sexual Function Trial Only- given every 3 months 
Erection Questions 
You will be asked questions about your ability to have erections and sex.  
Function Questions  
You will be asked questions about your sexual thoughts and activities.  
Tests for Participants in the Cognitive Function Trial Only- given every 6 months 
Memory for Designs Test  
You will be asked to remember designs that you have been shown from memory.  
Memory for Drawings Test 
You will be asked to pick out a drawing that you are shown from a set of many other 
drawings. 
Connect the Dots Test 
You will be asked to connect lines between numbered and lettered points on a page.  
Tests for Participants in the Vitality Trial Only- given every 3 months 
Quality of Life Questions 
You will be asked how you feel about your quality of life in several areas. This test has 
11 questions. This test will be done using the IVR phone system. 
Different Moods Questions 
You will be asked about your mood and feelings of anger from a list of words that 
describe different ways that you might feel. This test will be done using the IVR phone 
system. 
Study Schedule 
The chart below shows the schedule of tests during the time that you are in the study. In 
the 1st year there are 7 research site visits and 6 phone contacts. In the 2nd year there is 
1 research site visit and 1 phone contact.    
Study 
Phase 
Treatment Phase (1 Year) 
Monthly Clinic Visits or Phone Contacts 
Post-treatment 
Phase (1 Year) 
Visits Base line M 1 M 2 M 3 M 4 M 5 M 6 M 7 M 8 M 9 M 10 M11 M12 M18 M24 
Contact 
Type 
 
C 
 C C C P P C P P C P P C C P 
C = Clinic visit in person; P = phone contact 
 
V1.20080627 
Testosterone Trial Informed Consent Document - Appendix B  78
The research clinic visits and phone calls, and the tests and questionnaires that will be 
done are listed below.  
Baseline Visit 
For everyone: 
 Blood draw (2 tablespoons) 
 Measurements of height, weight, waist, hip, blood pressure 
 Rectal exam 
 Walking test 
 Medicines you are taking 
 Health problems and changes 
 Questionnaires at the research clinic about urinating, daily activities, falls,   
memory and mental sharpness 
 Questionnaires at home using IVR phone system about interest in sex,    
depression, moods, tiredness and mental sharpness 
For men in specific trials:  
 Physical Function Trial:  stair climbing test and physical abilities questionnaire 
 Sexual Function Trial:  questionnaires at the research clinic about erections and 
sexual function and questionnaires at home using IVR phone system about 
sexual thoughts and interest 
 Cognitive Function Trial: questionnaires at the research clinic about memory for 
designs and drawings  
 Vitality Trial:  questionnaires at home using IVR phone system about moods and 
feelings about your quality of life 
At the baseline visit you will be given the study gel and you will be shown how to use it.   
This visit will take 3 – 4 hours.  
Months 1 and 2 Visits 
At these visits you will be asked about the following:  
 Blood draw (1 tablespoon) for testosterone level only 
 Medicines you are taking 
 Health problems and changes 
You will be asked to bring your used study gel container with you to these visits and we 
will review the instructions for gel use. 
These visits will take about 30 minutes.  
Month 3 Visit 
You will be asked to bring your used study gel container with you to this visit and we will 
review the instructions for gel use. We will do the following tests and questionnaires with 
you:  
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All Participants 
 Blood draw (2 tablespoons) for testosterone level, PSA, hemoglobin and 
hematocrit 
 Measurements of height, weight, waist, hip, blood pressure 
 Rectal exam 
 Walking test 
 Medicines you are taking 
 Health problems and changes 
 Questionnaires at the research clinic about urinating, daily activities, falls,   
memory and mental sharpness 
 Questionnaires at home using IVR phone system about interest in sex, 
depression, moods, tiredness and mental sharpness 
For men in specific trials:  
 Physical Function Trial:  stair climbing test and physical abilities questionnaire 
 Sexual Function Trial:  questionnaires at the research clinic about your erections 
and sexual function and questionnaires at home using IVR phone system about 
your sexual thoughts and interest 
 Vitality Trial:  questionnaires at home using IVR phone system about your moods 
and feelings about your quality of life 
This visit will take 2 1/2 – 3 1/2 hours.  
Months 4 & 5 Phone Contact 
You will be contacted by telephone for these visits. The following assessments will 
occur for all subjects: 
 Medicines you are taking 
 Health problems and changes 
 Review of instructions for using the study gel 
These calls will take approximately 15 minutes. 
Month 6 Visit 
You will be asked to bring your used study gel container with you and review the 
instructions for gel use. We will do the following tests and questionnaires with you:  
All participants: 
 Blood draw (2 tablespoons) for testosterone level, hemoglobin and hematocrit 
 Measurements of height, weight, waist, hip, blood pressure 
 
 Walking test 
 Medicines you are taking 
 Health problems and changes 
 Questionnaires at the research clinic about urinating, daily activities, falls,   
memory and mental sharpness 
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 Questionnaires at home using IVR phone system about interest in sex, 
depression, moods, tiredness and mental sharpness 
For men in specific trials:  
 Physical Function Trial:  stair climbing test and physical abilities questionnaire 
 Sexual Function Trial:  questionnaires at the research clinic about erections and 
sexual function and questionnaires at home using IVR phone system about your 
sexual thoughts and interest 
 Cognitive Function Trial: questionnaires at the research clinic about your memory 
for designs and drawings  
 Vitality Trial:  questionnaires at home using IVR phone system about your moods 
and feelings about your quality of life 
This visit will take 3 – 4 hours.  
Months 7 & 8 Phone Contact 
You will be contacted by telephone for these visits. The following assessments will 
occur in all participants: 
 Medicines you are taking 
 Health problems and changes 
 Review of instructions for using the study gel 
These phone calls will take approximately 15 minutes. 
Month 9 Visit 
You will be asked to bring your used study gel container with you to this visit and we will 
review the instructions for gel use. We will do the following tests and questionnaires with 
you:  
All participants: 
 Blood draw (2 tablespoons) for T level, hemoglobin and hematocrit 
 Measurements of height, weight, waist, hip, blood pressure 
 Walking test 
 Medicines you are taking 
 Health problems and changes 
 Questionnaires at the research clinic about urinating, daily activities, falls,   
memory and mental sharpness 
 Questionnaires at home using IVR phone system about interest in sex, 
depression, moods, tiredness and mental sharpness 
For men in specific trials:  
 Physical Function Trial:  stair climbing test and physical abilities questionnaire 
 Sexual Function Trial:  questionnaires at the research clinic about your erections 
and sexual function and questionnaires at home using IVR phone system about 
your sexual thoughts and interest 
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 Vitality Trial:  questionnaires at home using IVR phone system about your moods 
and feelings about your quality of life 
This visit will take 2 1/2 – 3 1/2 hours.  
Months 10 & 11 Phone Contact 
You will be contacted by telephone for these visits. The following assessments will 
occur for all participants: 
 Current medicines 
 Health problems and changes 
 Review the instructions for using the study gel 
These phone calls will take approximately 15 minutes. 
Month 12 – End of Treatment Visit 
This is the last visit of the treatment phase. You will be asked to bring your used study 
gel container with you to this visit. We will do the following tests and questionnaires with 
you:  
All participants: 
 Blood draw (2 tablespoons) for testosterone level, PSA, hemoglobin and 
hematocrit 
 Measurements of height, weight, waist, hip, blood pressure  
 Rectal exam 
 Walking test 
 Medicines you are taking 
 Health problems and changes 
 Questionnaires at the research clinic about urinating, daily activities, falls,   
memory and mental sharpness 
 Questionnaires at home using IVR phone system about interest in sex, 
depression, moods, tiredness and mental sharpness 
For men in specific trials:  
 Physical Function Trial:  stair climbing test and physical abilities questionnaire 
 Sexual Function Trial:  questionnaires at the research clinic about erections and 
sexual function and questionnaires at home using IVR phone system about 
sexual thoughts and interest 
 Cognitive Function Trial: questionnaires at the research clinic about your memory 
for designs and drawings  
 Vitality Trial:  questionnaires at home using IVR phone system about your moods 
and feelings about your quality of life 
This visit will take 3 – 4 hours.  
Months 18 Assessment  
The follow-up visit at Month 18 may be held at the research clinic or at home.  
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 Blood draw (1 tablespoon) for PSA 
 Health problems and changes 
Months 24 Assessment  
The follow-up visit at Month 24 will be by phone to ask about health problems and 
changes.  
What are the risks of taking part in this research study? 
Risks of testosterone treatment 
Because testosterone might make certain conditions worse, if you take part in this study 
you will be tested before and during treatment to check for these conditions and to try to 
reduce the risk to your health.  These are the conditions that testosterone might make 
worse. 
Prostate cancer.  About half of men over age 65 have tiny areas of cancer in their 
prostate glands that appears not to hurt them. The worry is that testosterone treatment 
in this study could change these harmless tiny prostate cancers into harmful ones.  
When testosterone was given in previous studies to older men, there was not an 
increase in prostate cancer, but there is not enough research about older men using 
testosterone to know for certain how it will affect the chance of prostate cancer.  Also, 
some men who have prostate cancer have an improvement in the cancer if their blood 
testosterone is lowered.   
Men who have had prostate cancer or a pre-cancerous condition called PIN (prostate 
intra-epithelial neoplasia) will not be in the study. To reduce the chance that men who 
are in this study could have a worsening of an unknown cancer, only men who have a 
less than a 30% chance of any prostate cancer and less than a 7% chance of an 
aggressive prostate cancer will be allowed to be in the study. These possibilities will be 
figured out by using a combination of blood PSA results, age, race, family history of 
prostate cancer, absence of a prostate lump, and any results of a prior prostate biopsy, 
(sticking a needle into the prostate to get a sample to look at under the microscope) if 
one was done. Also, only men who do not have a prostate lump or hardness on the 
rectal examination will be in the study, unless a previous biopsy shows that the lump is 
not cancer.  
If your rectal exam does not show a lump, your estimated risk of any prostate cancer is 
about _____% and of aggressive (called high grade) prostate cancer is  about _____%.  
To check men in this study, we will repeat the blood PSA test at 3 and 12 months of 
treatment and again 6 months after stopping treatment.  If the blood PSA level 
increases by a certain amount, and the same result is found when we measure it again, 
we will recommend that you see a urologist to discuss whether you should have a 
prostate biopsy.  At that time, the urologist will go over with you the risk of having a 
prostate cancer compared to the problems of treatment for prostate cancer if one is 
found. 
V1.20080627 
Testosterone Trial Informed Consent Document - Appendix B  83
Enlarged prostate (Benign prostatic hyperplasia/BPH). Testosterone treatment of older 
men might also increase the size of the prostate and cause a decrease in urine flow.  
Other studies of testosterone treatment have not shown worsening of urination 
problems, but the number of men studied so far is too small to know for sure.  To 
reduce the chance of urination problems in this study, only men who do not have a lot of 
difficulty urinating will be eligible. This will be known by the score on the urination 
questionnaire. These questions will be asked again at 3 and 12 months. If the score 
goes up by 5 or more points, that will lead to us check for the cause of this problem. 
High red blood cell count (Erythrocytosis).  Testosterone normally increases the number 
of red blood cells, which is why men have higher red blood cell counts than women.  
However, if a man had a high red blood cell count when his testosterone was low, 
increasing the blood testosterone could increase his red blood cell count to higher than 
normal. This might increase the chance of a stroke. For this reason, only men with 
blood hemoglobin levels (a measure of red blood cells) below a certain value will be 
allowed to be in the study. In addition, the hemoglobin levels will be checked again at 3, 
6, and 12 months. An increase above normal will lead us to send you to another doctor 
to find out the cause of the increase. If no cause is found, the amount of gel that you 
use will be reduced. If the hemoglobin value does not go back to normal within one 
month, treatment will be stopped.   
Sleep apnea.  Testosterone may increase the risk of sleep apnea, a condition in which 
not enough oxygen gets into the blood during sleep, resulting in excessive sleepiness 
during the day.  Although it is not certain that testosterone has this effect, men who 
have been diagnosed with sleep apnea will be eligible only if they are being treated for 
it.  
Procedure Risks 
Physical Function Tests.  There is a risk that you may find the Walking Test or the Stair 
Climbing Test tiring or too hard to finish. Trained personnel will be there to check how 
you are during these tests. You may stop the test if you need to rest.  You may also 
stop to rest if you become tired because of the number of tests. 
Blood Draw.  Getting your blood drawn at the research clinic has a very small risk of 
temporary mild pain, bruising or infection at the place where the needle was stuck in the 
blood vessel. There is also the possibility of fainting because of anxiety or fear of 
needles. These risks are decreased by the use of trained people to draw your blood.  
Questionnaires.  Because some of the questionnaires are personal, some men may feel 
uncomfortable answering these questions. The most personal questions will be asked 
over the phone IVR system while you are at home so that you will have privacy.  Your 
answers will not be shared with anyone. All information that is collected will be 
considered private and only identified by a study code number. 
Memory Tests.  Testing of your memory may be stressful and tiring because they 
require you to think hard sometimes.  We just want you to try your best.  There are no 
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passing or failing grades on these tests, and you should not practice taking these tests 
at home to do better. 
Testosterone Gel.  If testosterone gets transferred from your skin to a woman’s or a 
child’s skin, she or he could develop male features. Transfer can be avoided by washing 
your hands. It is also important to allow the gel to dry thoroughly after applying it, and to 
keep the area where the gel was applied covered.   The gel contains alcohol and in 
some men may cause dry skin or skin irritation. 
Prostate Biopsy.  If a prostate biopsy is needed, it has two main risks, which are 
bleeding and infection. The standard safety measure to lower the chance of bleeding is 
to avoid medicines that thin your blood and prevent it from clotting normally, like aspirin, 
anti-inflammatory medicines (such as ibuprofen), and herbal supplements, before and 
after the procedure. The standard safety measure to lower the chance of infection is to 
give antibiotics. If you have a prostate biopsy, your doctor will give you complete 
instructions about taking antibiotics. By using these safety measures, the chance of 
bleeding or serious infection requiring hospitalization is  less than 1%. 
Unknown risks.  There is also a chance of a side effect that is not known at this time. 
Are there any benefits to taking part in this research study? 
You may not get any benefit from participating in this study. You may feel better or 
stronger, or you may not. Your health status will be checked frequently during the time 
that you are in the study. By taking part in this study you may improve our 
understanding of testosterone treatment.   
What happens if I decide not to take part in this research study? 
You are free to decide whether or not to be in this study.  Your care at this institution will 
not change if you choose not to be in this study or if you choose to withdraw from the 
study anytime after you start.  
How long will I be in the study? What if I want to leave the research study after I 
begin? 
You will be in the study for 2 years. You are free to leave the study at any time. 
Dropping out of the study will not interfere with your future care. 
Will confidential health information be collected as part of this study? 
Some private information about your health will be collected. There are forms that ask 
questions about your medical history, physical function as well as sexual function, 
memory and how you think, and your energy level and quality of life. Every attempt will 
be made to keep all information collected in this study strictly private. Authorized 
representatives of [Insert Institution], the University of Pennsylvania, and the National 
Institutes of Health may review and copy information collected from this study and your 
medical records. If any articles are published from the results of this research, you will 
not be identified by name. 
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What happens to the health information if you want to leave the study? 
If you leave from study, no additional information will be collected. Information that has 
already been collected and are part of the study will remain. You may ask that your 
stored blood samples be destroyed by writing a request to the Principal Investigator of 
the study. 
What will you do with the blood you collect?  
Blood that is left over after measuring the testosterone, PSA and other tests will be stored 
at the Mayo Clinical Trial Services Central Laboratory.  It may be used for future studies 
of the effects of testosterone. Information that identifies the blood as yours will be 
removed, so that the only connection of the blood to your study results will be a study 
code number, which you will be given at the time of you consent to be in the study. The 
blood will be stored through the end of the study, up to 5 years or more. It may be used 
at any time during that period for other studies of testosterone effects. It is possible that 
new tests might be available in the future, which could be useful in understanding 
testosterone. You will not be able to find out the results of these tests.    
Researchers who plan to use your blood sample for future research studies will ask 
permission from the National Institutes of Health and the investigators of this study 
before using your sample. Samples will be released only to scientists who are qualified 
and prepared to conduct a research study.   
What will it cost me to take part in this study? 
It will not cost you anything to be in the study. You will be contributing your time and 
energy. 
Will I be paid for taking part in this research study? 
You will be paid a small amount, which will be given to you as you complete study visits.  
If you complete the entire study, the total amount will be $750.  In addition, you will be 
reimbursed for travel expenses and parking and you will be provided meal tickets during 
the study visits. 
{This section can be customized per site.} 
What happens if I am injured during the study?  
In the event of a research-related injury, please contact your study doctor right away at 
the phone numbers provided on the front page of this form. 
In the event of any physical injury resulting from the research procedures, medical 
treatment will be provided without cost to you, but financial compensation is not otherwise 
available from {Customize this section in accordance with institutional policy.} 
You or your insurance company, if any, may be billed for medical expenses associated 
with this study only if they are believed to be medically necessary and not related to the 
study. {Customize this section in accordance with institutional policy.} 
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What if I have questions about the study? 
If you have questions, concerns or complaints about being in this research study, or if 
you have any questions about your rights as a research subject, you should speak with 
the Principal Investigator listed on page one of this form.  If a member of the research 
team cannot be reached or you want to talk to someone other than those working on the 
study, you may contact the {Institutional Office of Regulatory Affairs} with any question, 
concerns or complaints at Your Institution by calling {XXX)YYY-ZZZZ}. 
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SIGNATURE PAGE 
I have had this research study explained to me.  I have read the informed consent form.  
I have had the chance to ask questions.  My questions have been answered to my 
satisfaction.   
I understand that my signature below means that I voluntarily agree to take part in the 
research study.  I will be given a copy of this form for my records. 
     
Printed Name  Signature of Subject   Date
(Or Legally Authorized Representative – note relationship to subject) 
     
Printed Name  Signature of Witness   Date
(Only required if the subject cannot read this consent form)   
I have discussed this clinical study with the subject and/or his authorized representative, 
using language that is understandable and appropriate. I believe that I have fully 
informed the subject of the nature of this study and its possible benefits and risks.  
     
Printed Name  Signature of Person Obtaining Consent   Date
 
SEPARATE SIGNATURE REQUIREMENTS FOR OPTIONAL GENETIC SAMPLE  
We are also interested in collecting blood samples to store for future genetic studies.  
Details of the genetic sub-study are described in the attached genetic consent form.  
You are not required to take part in this portion of the study in order to be in the main 
part of the research study. 
Please indicate your interest in participating below: 
 
Please Initial 
Yes, I would like to know more about the genetic sub-study. If I decide 
to take part in the sub-study, I will sign a separate consent form. 
 
 
Please Initial 
No, I do not want to participate in the genetic sub-study. 
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Study Schedule  Treatment Phase (M = Month) Follow-up
Test or Procedure in All Participants Screen 
2 
Base-
line 
M 1 &  
M 2 
M 3 M 4 &  
M 5 
M 6 M 7 & 
 M 8 
M 9 M 10 & 
M 11 
M12  M18 M24
                  (Visit Type: C = Clinic Visit, P = phone contact) C            C C C P C P C P C C P
Informed consent  x            
Blood draw x            x x x x x x x
Your medicine x            x x x x x x x x x
Medical history x            
Health  problems & changes             x x x x x x x x x x
Gel instruction and review             x x x x x x x x
Height, weight, waist, hip, blood pressure x            x x x x x
Rectal exam x            x x
Urination questions  x            x x x
Walking Test x            x x x x x
Short memory test x            
Sex Diary – Question 4*             x x x x x
Memory for words x            x x x
Tiredness questions x            x x x x x
Change in the way you feel             x x x x x
Activities of daily living             x x x x x
Falls             x x x x x
Depression questions x            x x x x x
Mood questions*             x x x x x
Joint pain and stiffness questions x            
Sexual function questions x            
Nervousness and worry questions x            
Memory  questions x x           
Word knowledge test ‡  x        x   
Tests in Participants in Specific Trials:   
Physical: Physical Function Questionnaire-10, Stair climb             x x x x x
Sexual: Sex Diary* (complete), Erection questions, Sexual 
function questions 
            x x x x x
Cognitive: Memory of designs, drawings, connect the dots, 
general memory† 
            x x x
Vitality: Quality of life questions*, Different mood questions*             x x x x x
     (Key:  * administered by IVR, † 0 and 12 mos, ‡ 0 mo only)              
Multimedia Tool Development Proposal – Appendix C  89
MULTIMEDIA TOOL DEVELOPMENT PROPOSAL – April 4, 2008 
Title Development of an Informed Consent Multimedia Tool for Research 
Introduction -
Proposed Use 
This multimedia tool is being developed to accompany the informed consent 
document of a clinical trial in a geriatric population. Its purpose is to enhance 
the informed consent process by presenting the information in the informed 
consent document in a series of brief, focused teaching modules. These 
modules will include video and audio technology to guide the user through the 
module. Each module will conclude with a review section called “Check Your 
Understanding’ that asks the user to answer questions about the information 
that have just seen and heard. A summary of these responses will be made 
available to the research team presenting the informed consent document to 
provide a basis for review and clarification of the information presented in the 
module.  
Audience The users of this multimedia tool will be the potential participants of the 
Testosterone Trial, a clinical trial of testosterone efficacy in men aged 65 and 
older.  
Resources Funding for development of this tool will be sought from the research study 
sponsor. Research technology expertise will be contracted through the web 
services development department in the University of Pennsylvania School of 
Medicine.   
Personnel Content will be developed by a collaborative team of the following: 
- Denise Cifelli, Project Director. Ms. Cifelli, Director of Project Operations and 
Compliance in the Clinical Research Computing Unit, has led the project 
development effort from the proposal phase and will continue to direct the 
project into the implementation phase. She has developed the study 
protocol, informed consent documents, regulatory documentation and 
associated monitoring and quality assurance plans. 
- Peter J. Snyder, MD. Principal Investigator of the Testosterone Trial. Dr. 
Snyder is an endocrinologist at the University of Pennsylvania, School of 
Medicine and has conducted testosterone clinical research for over 30 
years. He will serve as the subject matter expert for the content presented in 
the tutorial.  
- Gregg Fromell, MD, Director, Office of Human Research, University of 
Pennsylvania, School of Medicine. Dr. Fromell provides expertise on 
research education and training, research compliance and quality 
improvement. He will serve as the subject matter expert on the essential 
elements of informed consent, readability and format of the material.  
- Barry Dornfeld, PhD. Educational Media Consultant. Dr. Dornfeld of the 
Center for Applied Research (CFAR) provides expertise in development of 
content and organization of biomedical knowledge and serves as a reviewer 
of the multimedia tool. 
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Content 
Development  
The content of the tutorial will parallel the information written in the informed 
consent document. Subject matter experts will review the tutorial for accuracy 
regarding the testosterone trial (Snyder), the essential elements of informed 
consent (Fromell) and overall tone, sequencing, cohesion and clarity (Dornfeld). 
The tutorial has been developed as a Powerpoint presentation. See Appendix 
A. This presentation will serve as the template for the development of the tool 
as a teaching module available from a secure server as well as a portable 
program. 
Availability of 
Technology 
The tutorial will be developed for use by participants who may access it from a 
web site on a secure server (hosted at the University of Pennsylvania 
Biomedical Research Computing environment) on the internet. This will be 
made available via a computer in a private location at the research clinic to 
serve those participants who are willing to read the informed consent and 
participate in the informed consent process during the baseline clinical research 
visit.  
The program must also be available on transportable media (DVD) so that a 
participant may take the DVD home to read the informed consent document and 
complete the accompanying tutorial in the privacy of their home, using a 
standard desk top computer. The requirements for the desk top computer must 
be of the type that are available on most recent model computer systems and 
not require “plug-ins” or files that must be downloaded in order to run the 
tutorial.  
Technology 
Features 
The tutorial must include the following features: 
1. Advance organizer. The first slide of the tutorial will instruct the user 
about the features of the tutorial described below. Audio will accompany 
this first slide as the mouse moves automatically over the features and 
tags appear to indicate the alternative keystroke that will perform the 
same function as the mouse. The second slide of the tutorial will 
describe the Check Your Understanding slides and features using the 
same audio and video technology.  
2. Table of Contents. Each segment of the module must be listed 
separately in a vertical table of contents so that it can be selected by 
one click of the mouse or keyboard stroke and begin at the first slide of 
that segment. 
3. Video streams must be sharp and clear. An indicator will appear over 
the video file and a tag will instruct the user to click the arrow to play the 
video. 
4. Volume adjustment keys with mouse-over tag to describe the function. 
5. Slide navigation keys to return to the previous slide or advance to the 
next slide. 
6. Repeat slide key. 
7. Slide counter to indicate slide number of total slides. (Example: Slide 3 
of 10). 
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8. Quit program key. This will allow the user to stop the tutorial and save 
their responses so that they can resume later and continue from that 
point.  
9. Check Your Understanding features will include the ability to click in a 
response check box and receive immediate reply indicating if response 
is correct or incorrect and accompanying information. (See Comment 
boxes on these slides as an example.) 
10. Responses to Check Your Understanding questions will be saved in a 
data table that can be generated as a report at the end of the program 
by the participant (if using the program at home) or by the person 
administering the tutorial (if the process is occurring at the research 
clinic.) This table should include complete information (the entire 
question, answers and explanations) be viewable and printable so that it 
may be used to discuss the informed consent issues that require clarity. 
11. The program must allow the user to pause or quit the program and 
resume where he left off, saving the responses completed to that point.  
Additional 
Requirements 
The tutorial will be provided to the software developer and programmer as a 
power point presentation. Video images and video streams will be provided and 
incorporated into the tutorial as indicated in the .ppt file. The project director will 
have final approval over the selection of the audio portion of the program. (The 
audio portion must be a male voice.) The functionality (described above) will be 
pilot tested by the project director before final implementation.  
Terms To be determined. 
Timeline To be developed. 
Contact 
Information 
Denise Cifelli 
cifelli@mail.med.upenn.edu 
Phone 215-573-4534 
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INTERVIEW QUESTIONS FOR POTENTIAL TESTOSTERONE TRIAL 
PARTICIPANTS (MEN 65 OR OLDER)  
EVALUATION OF INFORMED CONSENT DOCUMENT INTERVIEW SCRIPT 
Dated: February 9, 2008 
Interviewer:  I would like to ask your opinion about several things that have to do with a 
research study that is being planned at several medical centers in the US. It is about the 
use of testosterone in men aged 65 or older.  
Testosterone is not a new drug. It has been available for a few years and doctors can 
prescribe it.  Doctors are conducting this study to try to find out if using testosterone (it is 
often called “T”) leads to improved physical performance (for example: ability to walk, 
climb stairs, carry groceries), increased interest in sex, improved memory and improved 
overall sense of energy and zest for life.  
Before starting in the study there would be a few tests that must be done to check your 
testosterone level and other blood tests, as well as questionnaires that you will be asked 
to complete. For now, I would like to ask you 15 questions about the research consent 
form that I will give you to read.  
Interviewee initials:  ___ ___ ___ 
1. Are you willing to participate in this interview? ....................................... Yes   No   
2. Age  __________  years 
3. Level of education: 
1  6th grade or less 
2  7th to 12th grade, no high school diploma 
3  High school graduate or equivalent (e.g. GED) 
4  Technical or vocational school degree 
5  Some college education, but not completed degree 
6  College graduate 
7  Professional or graduate degree (e.g. Master’s, PhD, JD, MD) 
Directions:  I am going to give you several pages to read. It is an informed consent 
document that describes the research study. Please take your time and read it and 
let me know when you are finished.   
4. On the line below, please rate how easy or difficult it was for you to read the 
informed consent document. 
 
1 2 3 4 5 6 7 
Very easy Easy Somewhat 
easy 
Moderate Somewhat 
difficult 
Difficult Very 
difficult 
 
 
Comments: _________________________________________________________ 
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5. After reading this document, do you understand that you could be in 1, 2, 3 or 4 
separate trials depending on the information you give when asked about your 
physical abilities, sexual interest, memory or energy? ........................... Yes   No 
Comments: _________________________________________________________ 
6. A.  Do you understand the explanation about the testosterone gel and placebo 
(gel without medication) used in this study?  ......................................... Yes   No 
B.  Do you understand that you will not know which gel you are using and that 
the study doctors, nurses or other study staff members will not know either? ....  
..............................................................................................................  Yes   No 
Comments: _________________________________________________________ 
7. Do you understand the explanation about using the gel every day for a year and 
the steps that you should take to be sure that you use it safely?........... Yes   No 
Comments: _________________________________________________________ 
8. Do you understand the commitment that is being asked of you to in coming to the 
research site for tests and questionnaires 6 times over the first year and once 
during the second year?......................................................................... Yes   No 
Comments: _________________________________________________________ 
9. A. Do you understand what the IVR phone system is used for? ..........  Yes   No 
B. What do you think of using your home phone (or cell phone) to answer private 
questions?  
Comments: _________________________________________________________ 
10. Do you think you will be able to answer personal questions about your physical 
abilities, sexual life, memory and energy with the people at the research site?...  
..............................................................................................................  Yes   No 
Comments: _________________________________________________________ 
11. A. Do you understand the risks of being in this study? .........................  Yes   No 
B. Do you have concerns about the risks of taking testosterone? ........  Yes   No 
Comments: _________________________________________________________ 
12. A. Do you think being in this study is the kind of thing that you would be 
interested in doing? ............................................................................... Yes   No 
B. Would you be willing to talk about it with your spouse, partner, family or  
friends?..................................................................................................  Yes   No 
Comments: _________________________________________________________ 
13. Do you think it would be helpful to discuss this study with your own doctor? ......  
..............................................................................................................  Yes   No 
Comments: _________________________________________________________ 
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14. A. If the information in the consent form were given to you on a CD, would you be 
able to use a home computer or DVD player to view it?  
i. Computer?  ................................................................. Yes   No 
ii DVD player?................................................................. Yes   No 
B. If you were given a link to a website, would you feel comfortable reading this 
on the Internet? ...................................................................................... Yes   No 
Comments: _______________________________________________________ 
15. Do you have any questions or comments about this informed consent document, 
the research study or any other topics related to this discussion?........  Yes   No 
Comments: _______________________________________________________ 
Thank you very much for your time and for discussing this topic with me!!     
Notes:         
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EVALUATION OF INFORMED CONSENT DOCUMENT 
SUMMARY DATA AND COMMENTS 
Interview with Potential Subjects about the Testosterone Trial  
Dated: April 16, 2008 
1. Respondents  (n = 8) 
 Initials Age Eligible? 
1 ALC 77 No 
2 BLM 67 Yes 
3 PLH 71 No 
4 ABP 65 Yes 
5 LAD 75 Yes 
6 RMC 70 Yes 
7 RSR 80 No 
8 MIK 85 Yes 
2. Education  
Number 
(Percent) Level of Education 
1 (12.5%) 7th to 12th grade, no high school diploma 
4 (50%) High school graduate or equivalent (e.g. GED) 
1 (12.5%) Some college education, but not completed degree 
2 (25%) College graduate 
3. Age Group 
Range: 65 – 85 
Age Number (Percent) 
65 - 74 4  (50%) 
75 - 85 4  (50%) 
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4. Document Readability 
Number 
(Percent) Document Readability 
1 (12.5%) Very easy 
2 (25%) Easy 
2 (25%) Somewhat easy 
2 (25%) Moderate 
1 (12.5%) Somewhat difficult 
 
Question 
Number Question Yes No 
5. Knowledge of 4 separate trials about your physical 
abilities, sexual interest, memory or energy 
6 (75%) 2 (75%) 
6 A.  Explanation about the testosterone gel and placebo 8 (100%) 0 
6 B. Knowledge of treatment or placebo group 7 (87%) 1 (13%) 
7. Medication use and safety precautions 8 (100%) 0 
8. Time commitment and trial participation schedule 6 (75%) 2 (75%) 
9. IVR phone system 6 (75%) 2 (25%) 
10. Comfort regarding personal questions about physical 
abilities, sexual life, memory and energy with 
research staff. 
7 (87%) 1 (13%) 
11 A. Risks 8 (100%) 0 
11 B. Specific concerns about testosterone risks 6 (75%) 2 (25%) 
12 A. Potential interest 4 (50%) 4 (50%) 
12 B. Willingness to discuss with your spouse, partner, 
family or friends 
6 (75%) 2 (25%) 
13. Discuss this study with personal physician 8 (100%) 0 
14 A. Ability to use technology at home – computer 3 (38%) 5 (62%) 
14 B. Ability to use technology at home – DVD player 4 (50%) 4 (50%) 
14 C. Ability to use technology at home – Internet website 2 (25%) 6 (75%) 
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